Posts by acn:

BankPozitif’s Chairman Dr. Erkan Kork: Turkiye Will Continue to Attract Qualified Investments

ISTANBUL, August 19, 2024 (ACN Newswire via SeaPRwire.com) - Türkiye received $4.7 billion in international direct investment in the first six months of this year. The Netherlands, the USA, Germany, Ireland, Norway, and the United Kingdom were the countries from which Türkiye received the most investment capital.BankPozitif's Chairman, Dr. Erkan KorkCommenting on the issue, BankPozitif Chairman Dr. Erkan Kork stated that despite the global decline in international direct investments, Türkiye has performed better, saying, "Our country is attracting significant investments from global actors with its entrepreneurial business culture, young population, and competitive products and services. Over the last 20 years, Türkiye has become a country that attracts 1% of the world's investments annually. The goal is to increase this rate to 1.5% by working even harder. Türkiye is not far from this target with the political stability provided by our President Recep Tayyip Erdogan, the reforms implemented, infrastructure investments, and investor-friendly policies. Under the vision and determined stance of our Minister of Treasury and Finance, Mr. Mehmet Simsek, our country is on the path to becoming a center for international investments.""It would be no surprise to hear news of new investments"Noting that Türkiye would achieve a much different picture with price stability, Kork said, "Türkiye Cumhuriyet Merkez Bankası Governor Fatih Karahan and his team are, so to speak, working tirelessly day and night. The improvement in the current account balance is evident. Recently, with the increase in our reserves and the correct steps taken, the Turkish Lira has reached an attractive position. Achieving price stability opens the door to the process leading to financial stability. In a country where there is financial stability, the appetite for investment is high," he said."Large-scale investments will come in the fintech sector"Dr. Erkan Kork stated that Türkiye would continue to attract qualified investments, especially those focused on the export of goods and services, saying, "The total value of international direct investment inflows to our country since 2002 has exceeded $268 billion. The investments received in the first six months of 2024 accounted for 28% of the current account deficit. This rate will increase further. Türkiye, which is a production, logistics, and management center for international investors, will continue to attract technology investments, particularly in fintech and e-commerce. I believe that capital inflows will continue not only from Europe and the USA but also from the Gulf countries," Dr. Kork said.About BankPozitifOperating in the field of digital banking, BankPozitif is a Turkey-based financial institution that enables individuals and businesses to carry out their financial transactions quickly and efficiently through a single digital platform. The bank offers digital investment banking with personalized financial solutions and innovative technologies for its customers. Source: BankPozitif [https://www.bankpozitif.com.tr]This press release is issued through EuropeNewswire.Net (www.europenewswire.net) and distributed by EmailWire (www.emailwire.com) – the gloabal newswire that provides Press Release Distribution with Guaranteed Results™. Copyright 2024 ACN Newswire via SeaPRwire.com.

Q2 Metals Drills 120.3 M at 1.72% Li2O including 19.0 M at 2.06% in First Assays Reported from its Spring 2024 Drill Campaign at the Cisco Lithium Property, James Bay, Quebec, Canada

Highlights:Strong analytical results from the inaugural drilling campaign for Q2 Metals including:CS-24-010: Cumulatively 181.1 metres ("m") at 1.67% Li2OWidest interval of 120.3 m at 1.72% Li2O including 19.0 m at 2.06% Li2OCS-24-007: Cumulatively 94.6 m at 1.52% Li2OWidest interval of 27.1 m at 1.96% Li2O including 11.1 m at 2.49% Li2OCS-24-008: Cumulatively 27.0 m at 1.63% Li2OWidest interval of 19.3m at 1.75% Li2O including 6.2 m at 2.23% Li2OCS-24-009: Cumulatively 115.9 m at 1.48% Li2OWidest interval of 82.1m at 1.43% Li2O including 15.7 ma t 1.88% Li2OVancouver, BC, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - Q2 Metals Corp. (TSX.V:QTWO)(OTCQB:QUEXF)(FSE:458) ("Q2" or the "Company") is pleased to report on the first core assay results from drill holes CS-24-007 to CS-24-010 from the Spring 2024 Drill Campaign at the Cisco Lithium Property (the "Property" or the "Cisco Property") located within the greater Nemaska traditional territory of the Eeyou Istchee James Bay region of Quebec, Canada."These first four holes of our inaugural drill program at Cisco have exceeded our expectations with higher grades within some of the wider intervals such as Hole 10," said Q2 Metals VP of Exploration, Neil McCallum. "We look forward to releasing more analytical results in the coming weeks as they become available.""Between closing our financing earlier this month and the work we've done in the field, 2024 has been an exceptional year for Q2 Metals so far," said Q2 Metals President and CEO, Alicia Milne. "We have just begun our work at the Cisco Property, and having only completed 12 drill holes, these initial results are exceptionally promising."The analytical results reported herein represent the first 1,017 m of drilling over four (4) holes of the 3,753 m that were drilled over 12 holes at the Cisco Property. Initial visual results of those four holes were reported by the Company on June 17, 2024.The Spring 2024 Drill Campaign was designed to expand upon the 2023 drilling by the Property vendors. Hole CS-23-05 ("Hole 5") drilled by the Property vendor ended in pegmatite and assays results confirmed a total of 115.4 m at 1.40% Li2O, cumulatively within five (5) separate pegmatite intervals. Holes CS-24-009 and 010 ("Hole 10") were designed as 50 m westward step-outs from Hole 5. Assay results from these two holes confirmed wide intervals of spodumene pegmatite, with the widest interval reaching 120.3 m at 1.72% Li2O, including 19.0 m at 2.06% Li2O in Hole 10.Complete highlighted intervals from holes CS-24-007 to 010 are summarized in Table 1 and represented in Figure 1. All intervals of greater than two (2) metres of core-length are included in the table. Internal dilution of non-pegmatite material was limited to intervals of less than five (5) metres. No specific grade cap or lower cut-offs were used during grade and width calculations. All intervals are reported as core widths and mineralized intervals in all the holes drilled thus far are not representative of the true width as the modelled pegmatite zones are being refined with every additional hole.Figure 1. Map of Inaugural Drill Hole Analytical Results at Cisco PropertyTable 1. Summary of Analytical Results of Spring Drill Holes at Cisco PropertyResults from approximately 2,700 m of drilling eight (8) holes (CS-24-011 to CS-24-018) remain to be reported from the Spring 2024 Drill Campaign and will be released as soon as results are available. Drilling at the Cisco Property is ongoing and will continue into the fall of 2024.About the Cisco PropertyThe Cisco Property is comprised of 222 mineral claims and is 11,374 hectares in size. It is located less than 10 kilometres ("km") east of the Billy Diamond Highway, and is approximately 150 km north of Matagami, a small town that contains the closest rail link to much of James Bay. The Property lies within the greater Nemaska Community lands of the Eeyou Istchee Territory, James Bay, Quebec.The Property is situated along the Frotet Evans Greenstone Belt, comprised of a volcanic package dominated by mafic to felsic metavolcanic rocks, of the southern James Bay Lithium District, the same belt that hosts the Sirmac and Moblan lithium deposits, located 130 km and 180 km away, respectively.Sampling, Analytical Methods and QA/QC ProtocolsAll drill core samples were shipped to SGS Canada's preparation facility in Val D'Or, Quebec, for standard sample preparation (code PRP92) which includes drying at 105°C, crushing to 90% passing 2 mm, riffle split 500 g, and pulverize 85% passing 75 microns. The pulps are then shipped by air to SGS Canada's laboratory in Burnaby, BC, where the samples are homogenized and subsequently analyzed for multi-element (including Li and Ta) using sodium peroxide fusion with ICP-AES/MS finish (code GE_ICM91A50).A Quality Assurance / Quality Control protocol following industry best practices was incorporated into the sampling program.Qualified PersonNeil McCallum, B.Sc., P.Geol, is a registered permit holder with the Ordre des Géologues du Québec and Qualified Person as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects, and has reviewed and approved the technical information in this news release. Mr. McCallum is a director and VP Exploration for Q2.About Q2 Metals CorpQ2 Metals is a Canadian mineral exploration company focused on unlocking its portfolio of lithium projects in the Eeyou Istchee James Bay region of Quebec, Canada, that includes both its 100-per-cent-owned Mia Lithium Property and the Cisco Lithium Property.The Cisco lithium property is located approximately 150 km north of Matagami, Que., and comprises 222 mineral claims and is 11,374 ha in size. The property has district-scale potential with an already identified mineralized zone and a discovery drill result of 115.4 metres at 1.40 percent lithium oxide (hole CS-23-05), cumulatively in five separate pegmatites.FOR FURTHER INFORMATION, PLEASE CONTACT:Alicia MilnePresident & CEOAlicia@Q2metals.comJason McBrideCorporate CommunicationsJason@Q2metals.comTelephone: 1 (800) 482-7560E-mail: info@Q2metals.comWWW.Q2Metals.comFollow the Company: Twitter, LinkedIn, Facebook, and InstagramForward-Looking StatementsThis news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian legislation. Forward-looking statements are typically identified by words such as: "believes", "expects", "anticipates", "intends", "estimates", "plans", "may", "should", "would", "will", "potential", "scheduled" or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. Accordingly, all statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, any statements or plans regard the geological prospects of the Company's properties and the future exploration endeavors of the Company. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Forward-looking statements are based on a number of material factors and assumptions.Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in such forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date specified in such statement. Forward looking statements in this news release include, but are not limited to, drilling results on the Cisco Property and inferences made therefrom, the potential scale of the Cisco Property, the focus of the Company's current and future exploration and drill programs, the scale, scope and location of future exploration and drilling activities, the Company's expectations in connection with the projects and exploration programs being met, the Company's objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from those in forward-looking statements include failure to obtain necessary approvals, variations in ore grade or recovery rates, changes in project parameters as plans continue to be refined, unsuccessful exploration results, changes in project parameters as plans continue to be refined, results of future resource estimates, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, risks associated with regulatory changes, defects in title, availability of personnel, materials and equipment on a timely basis, accidents or equipment breakdowns, uninsured risks, delays in receiving government approvals, unanticipated environmental impacts on operations and costs to remedy same. Readers are cautioned that mineral exploration and development of mines is an inherently risky business and accordingly, the actual events may differ materially from those projected in the forward-looking statements. Additional risk factors are discussed in the section entitled "Risk Factors" in the Company's Management Discussion and Analysis for its recently completed fiscal period, which is available under Company's SEDAR profile at www.sedarplus.ca.Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.SOURCE: Q2 Metals Corp. Copyright 2024 ACN Newswire via SeaPRwire.com.

The Perse School (Singapore) to Launch New Campus in 2025

SINGAPORE, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - The Perse School (Singapore) (TPSS) has won the tender conducted by the Economic Development Board (EDB) and Singapore Land Authority (SLA) in the first half of 2024 to provide foreign system education on the site at 58 Chestnut Drive.Under new leadership, led by CEO Johan Stromsater and school principal, Daniel Cross, TPSS targets a launch on the new campus in January 2025 with a future-focused Cambridge curriculum to equip students with academic, critical thinking, problem-solving, and leadership skills. TPSS is working towards ERF registration, and subject to regulatory approval, will open to students from 3-11 years of age from January 2025 and extend to include 12-18 years of age from 2026. This development marks the beginning of an exciting phase for TPSS as the new management seeks to offer a blend of British academic excellence, co-curricular opportunities, and pastoral care for students with fees starting at $22,750 per year."We are excited to bring The Perse's long-standing tradition of excellence to the International School sector in Singapore at a fee level that will make a top tier British education attainable," says Johan Stromsater, CEO of TPSS. “Our mission is to nurture happiness and success among our students, and we are committed to developing a diverse student community and an inspiring educational environment where every student can thrive."“Singapore’s diverse and high-quality selection of Foreign System Schools enhances our competitiveness as an attractive location for international companies and global talent. The Perse School (Singapore) will add to the landscape and serve the varied education needs of expatriate families here,” said Ms Ho Weng Si, Senior Vice President, Industry Manpower Development, EDB.The leadership team comprises:Johan Stromsater: CEO of Futuris Education and now CEO of TPSS, previously served as CEO of the Canadian International School in Singapore.Daniel Cross: Founding Principal of TPSS, is relocating to Singapore from Cambridge after 24 years at The Perse School Cambridge, most recently as Senior Deputy Head. "I am thrilled to bring the rich traditions and academic excellence of The Perse School to Singapore. We aim to provide a world-class education that blends academic rigour with a modern, future-focused skills curriculum."Kephren Sherry will be the Head of Pelicans (Early years) and Junior School, with 28 years in education and 12 years in the international school system. "Joining The Perse School Singapore is an incredible opportunity to shape the future of education for thousands of children."Innovative CurriculumTPSS will offer a comprehensive education from early years (3 years) to senior school (18 years). The school's curriculum will prepare students holistically for the challenges and opportunities of the future, equipping students with academic rigour, critical thinking, problem-solving, and leadership skills. The Pelican Junior and Senior programs will follow the International Cambridge curriculum until iGCSE, with Years 12 and 13 adopting the International Baccalaureate (IB). The curriculum will have a strong emphasis on STEM subjects and bilingual programs, and will also integrate skills such as robotics, coding, and entrepreneurship into the core timetable.State-of-the-Art FacilitiesThe new campus will be located at 58 Chestnut Drive, the former site of Chestnut Drive Secondary School. The campus is undergoing significant renovations to create a state-of-the-art learning environment, with facilities that will include modern classrooms, a multi-purpose sports field, and specialised arts, music, and drama learning spaces. The first phase of the development is expected to be completed in time for the school opening in January 2025, with further development phases planned outside of school term time throughout 2025.Mission and Values of The Perse School SingaporeTPSS is under licence from The Perse School Cambridge International who will closely support the schools design and setup. With over 400 years of British academic excellence and heritage, the setup will be guided by a commitment towards academic excellence, extracurricular activity, and pastoral care to nurture well-rounded students. This is underpinned by The Perse core values of Endeavour, Intellectual Curiosity, Breadth and Balance, and Care for One Another and the Environment.Ed Elliott, Head of The Perse School Cambridge, remarks: "The close collaboration between our campuses will ensure the consistent delivery of The Perse's high standards and values. In a typical year, 40-50 Perse Cambridge pupils will receive offers from Oxford or Cambridge Universities. Perse Cambridge students received a combined 718 university offers this year, including 589 from the UK's prestigious Russell Group universities. Our success in university placements stems from an excellent academic education, complemented by our commitment to individual personal development through extracurricular programs like our Perse Exploration Society. These initiatives prepare students for further education, employment and adult life. Offering pathways to higher education and careers has been a hallmark of The Perse for centuries, and we aspire to extend these opportunities to our students in Singapore."A bank of imagery available for media use, including the leadership team, can be found on this drive link.About The Perse School (Singapore)The Perse School (Singapore), owned and operated by Future Education PTE LTD, offers an outstanding education affiliated with The Perse School Cambridge International. Perse Singapore's focus is on academic excellence, extracurricular activity, and pastoral care to nurture rounded students. Our core values—Endeavour, Intellectual Curiosity, Breadth and Balance, and One Another and the Environment—guide and shape the school's culture.About The Perse School CambridgeThe Perse School offers an excellent academic education complemented by extracurricular programs like the Perse Exploration Society. For more details, visit www.perse.co.uk.Contact: knsawtell@perse.co.uk  or sdarmitage@perse.co.ukContact Information:For media enquiries or more information, please email Contact@perse.com.sg. Social Media Links:Facebook Instagram: @Theperseschoolsingapore LinkedIn http://www.Perse.com.sgFor more information, please visit www.perse.com.sg Copyright 2024 ACN Newswire via SeaPRwire.com.

Qunabox Interim Report Announced: Revenue and Profit Continue to Grow

HONG KONG, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - Entering mid to late August, the Hong Kong stock market began to enter the peak period of interim report disclosure. Some high-quality enterprises, with their unique business models and outstanding performance in management and operation, achieved significant performance growth and stood out in the Hong Kong stock market, such as Qunabox Group (00917. HK).Revenue and profit continue to grow significantly, set to be included in Hong Kong Stock Connect in SeptemberQunabox Group is the largest AI interactive terminals network company in China and also the pioneer in providing AloT marketing solutions through experiential intelligent terminals. It uses AI interactive terminals to deliver innovative, engaging and immersive product experiences which align with evolving market trends and consumer needs. It effectively connects fast-moving consumer goods (FMCG) brands with their customers and consistently delivers comprehensive marketing solutions that seamlessly integrate both online and offline channels, addressing a variety of scenarios.Qunabox Group was listed on the main board of the Hong Kong Stock Exchange in May 2024. As a newly listed company, in the first half of 2024, the Company delivered an impressive results in its debut after going public with innovative marketing models, precise market positioning, and efficient service execution.On 15 August, Qunabox Group released its 2024 interim results report. Data shows that in the first half of 2024, the Company recorded revenue of RMB515.1 million, representing a year-on-year increase of 41.7%; gross profit of RMB281.4 million, representing a year-on-year increase of 45.0%; and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of RMB121.4 million, representing a year-on-year increase of 35.9%. As at 30 June 2024, cash and cash equivalents and restricted cash amounted to RMB887.6 million. The rapid growth of performance, stable financial condition, and adequate liquidity not only demonstrate the Company's strong market competitiveness and growth potential, but also provide solid financial support for the Company's long-term high-quality development.According to the announcement of Hang Seng Indexes Company on 16th August, Qunabox Group has been successfully selected to be included as a constituent change of the Hang Seng Composite Index, which will become effective on 9th September. After the inclusion in Hong Kong Stock Connect, the Company will receive more attention from investors and its liquidity is expected to be further enhanced.Well recognized by market, AI interaction marketing becomes the main driving force for performance growthPublic information shows that Qunabox Group's business mainly includes marketing services, merchandise sales and other services, among which, marketing services revenue accounts for nearly 80%, being the core business segment of the Group.In terms of marketing services, in the first half of 2024, Qunabox Group accurately grasped market dynamics and industry development trends, continuously improved service capabilities and operational efficiency, and achieved significant growth in both customer base and revenue. During the period, revenue from marketing services segment amounted to RMB411.8 million, representing a year-on-year increase of 41.1%, and gross profit amounted to RMB245.7 million, representing a year-on-year increase of 42.9%, driving significant growth in the overall performance of the Company. In terms of customers, during the period, the Group provided marketing services to a total of 171 brand customers, representing an increase of 41 customers as compared to the same period last year; among them, the number of KA customers served was 30 and the average revenue per KA customer was RMB10.6 million, both of which increased as compared to the same period last year. It demonstrates the brand customers highly recognize the value of Qunabox’s marketing solution which is based on AI interactive terminal.In terms of the merchandise sales, in the first half of 2024, benefiting from the overall recovery of the consumption industry, improved effectiveness of its terminal network and its more cost-effective pricing strategy, Qunabox Group’s AI interactive terminals significantly enhanced their capabilities in merchandise sales, driving continuous growth in the merchandise sales business, with a substantial increase in the number of offline terminals. During the period, revenue from the merchandise sales business segment amounted to RMB78.4 million, representing a year-on-year increase of 48.8%, and gross profit amounted to RMB24.1 million, representing a year-on-year increase of 69.7%. Revenue from merchandise sales per terminal per day amounted to RMB58.9, an increase of 25.2% year-on-year, which further consolidated the Company’s leading position in the market.In addition, leveraging its technological strengths in the AIoT sector, growing demand for related developments, and its solid reputation, customer demand and the number of projects have continued to grow. This has driven revenue generated from other services increasing from RMB19.0 million in the first half of 2023 to RMB24.9 million in the first half of 2024, representing a year-on-year increase of 30.8%. This growth fully demonstrates the Company’s strong capabilities in the technical service sector.Continuously increasing investment in technology and data to enhance brand market competitivenessTechnology and data serve as pivotal sources of innovation for enterprises, constituting their fundamental competitive advantage. As China’s leading AI interaction marketing service provider, in the first half of 2024, Qunabox Group continued to increase its efforts to develop offline marketing activities featuring AI interactions, encouraging its intensified technical experts to deeply engage in the design of marketing activities. This aims to expand the application scenarios and range of multi-sensory AI interactions, such as scent emission, motion detection, and voice interaction, while also extending emotion recognition technology in a bid to further enrich the forms of AI interactions and improve service capabilities. In the domain of data and algorithm, Qunabox Group has consistently driven the exploration of data value and the commercialization of product to enrich its data product offerings. At the same time, it has also improved the performance of AI interactive terminals and the efficiency of internal operation.According to the interim report, the Company’s R&D expenditure increased from RMB27.3 million in the first half of 2023 to RMB37.5 million in the first half of 2024, representing a year-on-year increase of 37.3%. Continuous investment in R&D not only brings the Company the ability to upgrade its services and improve efficiency, but also lays a solid foundation for the Company’s business expansion and steady development in the future.Expanding into overseas markets for a second growth curveQunabox Group has officially announced the launch of its internationalization strategy, with the Middle East market serving as the first stop in its expansion into overseas markets. This further expands the Company’s development space and is expected to drive accelerated growth in its performance.In the medium to long term, as the consumer market will witness further revitalization, the consumer goods marketing industry is anticipated to become even more dynamic. The multi-channel, one-stop, closed-loop marketing solutions provided by Qunabox Group based on the AI interactive terminal network will be accepted and applied by more brands with its advantages of being more innovative, efficient, and precise, and its market value will continue to increase. Copyright 2024 ACN Newswire via SeaPRwire.com.

Retail Revolution in the Age of AI: Rockbird Media Launches 12th Retail and E-Commerce Summit Asia in Singapore

SINGAPORE, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - A clear testament to the success of its past editions, Rockbird Media is thrilled to announce the 12th Retail & E-Commerce Summit Asia, set to unfold on September 26, 2024, at the One Farrer Hotel in Singapore. Themed “Retail Revolution: The Limitless Growth in the Age of AI,” this premier event is poised to dive deep into the seismic shifts reshaping the retail and e-commerce landscape.Despite its smaller population compared to regional neighbors, Singapore is on track to achieve a remarkable US$5,901 million in retail and e-commerce revenue by 2024. This impressive growth highlights the city-state's burgeoning role in the global digital economy and underscores the urgent need for businesses to adapt and thrive in this dynamic environment.The summit will offer an unparalleled opportunity for industry professionals to explore the latest trends and technologies driving the retail revolution. Attendees will benefit from keynote presentations, interactive breakout sessions, and panel discussions featuring leading experts. Personalized agendas, 1-on-1 meetings, and vibrant networking sessions will also be integral to the event, ensuring that each participant gains actionable insights and valuable connections.Singapore stands at the forefront of e-commerce innovation, and this summit will provide crucial insights into harnessing AI and technology for limitless growth, bringing together 100+ industry leaders and experts to shape the future of retail.For more information, including registration details, the in-depth agenda, speaker updates, pricing, and more, please visit https://rockbirdmedia.com/all_b2b/resa-singapore-2024/.About rockbird mediaRockbird media is an international business media company that produces B2B events and offers business solutions.Whether it is through online media and content, must-have business intelligence and analytics, effective networking, and partnering solutions, we help businesses and professionals learn more about the latest trends, and know more about their customers, peers, and competition, to make that decision that allows them to grow.Media contact:annjubelle@rockbirdmedia.com Copyright 2024 ACN Newswire via SeaPRwire.com.

Rockbird Media Unveils 16th HR Leaders and HR Tech Strategy Meeting: ‘Advancing into the Nexus of Human and Technology’ in Kuala Lumpur

KUALA LUMPUR, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - With rapid HR advancements on the horizon, Rockbird Media is just in time to announce the 16th edition of the HR Leaders & HR Tech Strategy Meeting, taking place on September 24, 2024, at Berjaya Times Square, Kuala Lumpur, Malaysia. The event, themed “Advancing into the Nexus of Human and Technology,” will be a crucial platform for addressing the evolving role of technology in HR.As Malaysia’s HR Technology market is poised for a significant 12% compound annual growth rate (CAGR) over the next five years, this year’s gathering will focus on equipping HR professionals with strategies to integrate cutting-edge tools and bridge the technological skill gap. Attendees will explore methods to enhance operational efficiency, boost employee engagement, and optimize legacy systems with modern technology.One in a series of successful HR Strategy Meetings across Southeast Asia, its 16th edition will emphasize the urgent need for HR leaders to strategically adapt to technological advancements, providing a unique opportunity to engage with industry experts, share best practices, and prepare for the future.The event will feature keynote addresses, interactive breakout sessions, panel discussions, and one-on-one meetings, designed to offer actionable insights and foster networking among over 100+ CHROs and HR leaders from various industries.For more information, including registration details, the in-depth agenda, speaker updates, pricing, and more, please visit: https://rockbirdmedia.com/all_b2b/hrmy2024/About rockbird mediaRockbird media is an international business media company that produces B2B events and offers business solutions.Whether it is through online media and content, must-have business intelligence and analytics, effective networking, and partnering solutions, we help businesses and professionals learn more about the latest trends, and know more about their customers, peers, and competition, to make that decision that allows them to grow.Media contact:annjubelle@rockbirdmedia.com Copyright 2024 ACN Newswire via SeaPRwire.com.

趣致集團中報出爐:收入利润持续增長 9月即將入通

香港, 2024年8月19日 - (亞太商訊 via SeaPRwire.com) – 步入8月中下旬,港股市場開始進入中報披露高峰期,部分優質企業憑藉自身獨特的業務模式,以及在管理和運營方面的卓越表現,取得了顯著的業績增長,成為港股市場中的佼佼者,例如趣致集團(00917.HK)。收入利润持续大幅增長  9月即將入通趣致集團是中國最大的AI互動終端網絡公司,也是以體驗式智能終端提供AloT營銷解決方案的首創者。其以AI互動終端為觸點,提供適應市場更新迭代和消費者需求的創新、有趣、沉浸式的産品體驗,連結快消品品牌與消費者,並持續爲品牌客戶提供綫上綫下相結合,適應多場景的全方位的營銷解決方案。趣致集團於2024年5月在香港聯交所主板掛牌上市。作為一家新晉上市公司,2024年上半年,公司憑藉創新的營銷模式、精准的市場定位以及高效的服務執行,為其上市後的業績首秀交出了亮眼的成績單。8月15日,趣致集團發佈2024年中期業績報告。數據顯示,2024年上半年,公司錄得收入人民幣5.15億元,同比增長41.7%;錄得毛利人民幣2.81億元,同比增長45.0%;經調整EBITDA為人民幣1.21億元,同比增長35.9%。於2024年6月30日,現金及現金等價物以及受限制現金達人民幣8.88億元。高速增長的業績、穩健的財務狀況以及充裕的流動資金,不僅展現出了公司強大的市場競爭力和增長潛力,也為公司的長期高質量發展提供了堅實的財務保障。據恒生指數有限公司8月16日公告,趣致集團已成功獲選,被納入【恒生綜合指數】的成分股,其將於9月9日正式生效。入通後,公司將獲得更多投資者關注,公司流動性有望進一步提升。AI互動營銷受市場認可 成業績增長的主要推動力公開資料顯示,趣致集團的業務主要包括營銷服務、商品銷售及其他服務板塊,其中營銷服務收入佔比近8成,為集團核心業務板塊。營銷服務業務方面,2024年上半年,趣致集團精准把握市場動態和行業發展趨勢,不斷提升服務能力和運營效率,在客戶基礎和營收方面均實現了顯著增長。期內,營銷服務業務板塊收入達人民幣4.12億元,同比增長41.1%;毛利為人民幣2.46億元,同比增長42.9%,推動公司整體業績大幅增長。在客戶方面,期內公司共為171名品牌客戶提供了營銷服務,較去年同期增加了41名;其中,服務的大客戶數為30名,大客戶的每名客戶平均收入為人民幣1,060萬元,兩者較去年同期均實現了增長,表現了品牌客戶對於其所提供的基於AI互動終端營銷解決方案價值的認可。商品銷售業務方面,2024年上半年,得益於消費行業的整體復蘇,終端網絡效能的提升以及更具性價比的定價策略,趣致集團的AI互動終端在商品銷售方面的能力得到顯著提升,推動商品銷售業務持續增長,線下終端數量顯著增加。期內,商品銷售業務板塊收入達人民幣7,845萬元,同比增長48.8%;毛利為人民幣2,410萬元,同比增長69.7%。單終端的單日商品銷售收入為人民幣58.9元,同比上升25.2%,進一步鞏固了公司在市場中的領導地位。此外,憑藉在AIoT領域的技術領先優勢、不斷擴展的相關開發需求,以及公司在行業中的良好聲譽,客戶需求和項目數量持續增長,推動其他服務收入從2023年上半年的人民幣1,905萬元,顯著上升到2024年上半年的人民幣2,491萬元,同比增長30.8%,充分反映了公司在技術服務領域的雄厚實力。不斷加碼技術和數據投入  提升品牌的市場競爭力技術和數據是企業創新的源泉,亦是企業的核心競爭力。作為中國AI互動營銷服務的領導者,2024年上半年,趣致集團持續提升人工智能交互線下營銷活動的開發力度,推動技術專家深入營銷活動設計的經營實踐,以擴大氣味散發、動作識別、語音交互等多感官AI互動的應用場景、適用範圍,同時拓展了情緒識別技術以進一步地豐富AI互動的形式,增強服務能力。在數據和算法方面,趣致集團一方面持續推動數據價值的挖掘和產品商業化開發,豐富數據產品;另一方面也不斷提升AI互動終端網絡的效能和內部運營效率。中報數據顯示,公司研發開支由2023年上半年的人民幣2,731萬元增加至2024年上半年的人民幣3,748萬元,同比增長37.3%。持續的研發投入,不僅為公司帶來了服務升級和提效的能力,還為公司後期的業務擴張和穩健發展打下牢固根基。開闢海外市場  或迎第二增長曲線趣致集團目前已正式宣布啟動國際化戰略,中東市場將作為其海外市場開闊的第一站,這進一步擴展了企業的發展空間,有望助推業績的加速發展。中長期而言,隨著消費市場將迎來更深層次的復蘇,消費品營銷市場亦將因此變得更加活躍和繁榮。趣致集團基於AI互動終端網絡提供的多渠道、一站式、閉環的營銷解決方案,憑藉其更創新、高效、精準的優勢,將被更多品牌所接受和應用,其市場價值將不斷提升。 Copyright 2024 亞太商訊 via SeaPRwire.com.

降本增益成果顯著 百利達集團2024年中期毛利率升至22.1%

香港, 2024年8月16日 - (亞太商訊 via SeaPRwire.com) – 百利達集團控股有限公司(「百利達集團」或「集團」,股票編號:8179.HK)欣然公佈,截至二零二四年六月三十日止未經審核中期業績,業績表現良好,期內降本增益成果顯著,業務規模及盈利能力持續上升,中期純利升5.05%,毛利率升至約22.1%。業績亮點:葡萄酒貿易續為主營業務 推動集團毛利率上升集團的葡萄酒主要來自多個著名澳洲葡萄園及釀酒廠,著重以優質葡萄酒為主要產品。2024年中期,葡萄酒貿易繼續為集團最大收益分部,期內收益約218.8百萬港元,同比略微減少30.3百萬港元;分部溢利45.2百萬港元,同比微降0.4%。主要受國內前景不明朗及消費者購買力下降所影響,然而得益於供應商提供更多折扣及產品銷售套餐,使得銷售成本減少15.81%,從而帶動集團毛利率提升3.4個百分點至22.1%。集團日前正積極拓展本地市場,包括參加各類展覽會、在不同地區發展銷售網絡及代理,並透過新零售模式建立多種銷售渠道。展望未來,集團葡萄酒產能穩步提升。2024年在收穫葡萄的同時,集團正在生產約55,000升葡萄酒。產能的增加將使集團能夠推出新品牌、開發罐裝紅葡萄酒以及進行產品升級。相信該等措施將更能滿足不同消費者群體不斷變化的需求及偏好。未來集團亦不排除將與有影響力的合作夥伴合作,從而持續建立品牌認知度,提升品牌價值。相信隨著「百利達」品牌價值的不斷提升,能對集團銷售額及市場份額帶來正面拉動,從而增加收入和利潤,進而帶來更大的股東價值。食品業務審慎經營 新產品飲用水拓無限商機集團食品業務主要包括澳洲百鶴年橄欖油等,於2024年中期,食品業務收益約為43,000港元。集團計劃於今年下半年開始推出源自慕士塔格峰的優質飲用水產品。飲用水產品較其他軟性飲料需求更為剛性,是外出場景解渴、室內場景飲水的首選。且隨著居民健康意識提升,瓶裝水對其他含糖飲料的替代也有望為產業發展貢獻增加。瓶裝水為中國軟飲行業界第一大賽道,數據顯示,2023年,中國瓶裝水產業市場規模達2,266億元人民幣,年增2.8%,銷售量則為528.8億公升,年增1.1%;預計2026年中國瓶裝水市場規模將成長至2,485.9億元人民幣,未來三年CAGR為3.1%,銷量將成長至545.2億升。相信集團優質飲用水新產品將繼續受益於瓶裝水好賽道帶來的無限商機。集團亦會持續關注市場情况,積極尋求潛在的增長及擴張機會。百利達集團主席兼執行董事黃巍女士表示:「百利達集團正積拓展市場,不斷提升品牌價值,從而吸引更多本地市場及亞太地區的潜在客戶。展望未來,集團將維持審慎的經營策略,集中資源開發最具增長潛力及盈利能力的商機 ,以維持盈利能力及穩定的業務經營,以最大程度提升股東回報。」- 完 -關於百利達集團控股有限公司百利達集團控股有限公司於1998在香港成立, 2011年在香港聯合交易所有限公司創業板上市。集團目前的主要業務為葡萄酒貿易業務、及於香港生產及銷售食品。百利達集團的葡萄酒貿易業務旨在利用香港葡萄酒業的穩定增長,是發展集團分銷和批發渠道的良機,並有助於使集團業務多元化。集團主要品牌「百利達」的葡萄酒主要來自多個著名澳洲葡萄園,著重以優質紅酒為主要產品。集團的葡萄酒現已銷往超過12個國家和中國28個地區,並在韓國新羅免稅店及韓國現代百貨免稅店上架,廣受五星級酒店、航空公司以及各類中式、日式、西式餐廳等歡迎。同時,集團自2006年開始生産、銷售及分銷食品,食品業務分部透過自營零售店為香港客戶生產及供應燒臘及台式滷味等食品,及供應至香港的本地大型連鎖超市等。傳媒查詢:  意博資本文化有限公司   電話:3476 2915    電郵: ir_palinda@vsfg.com Copyright 2024 亞太商訊 via SeaPRwire.com.

OrbusNeich Records Net Profit of US$18.8 Million for the First Half of 2024

Results Highlights:- Revenue and net profit reached US$78.9 million and US$18.8 million, respectively.- APAC market revenue grew significantly by 31.0%, driven by both organic growth and contributions from SJ Medicare and PT Revass, the South Korean and Indonesian distributors acquired in Q4 2023.- Total sales volume of proprietary products remained at 717,000 units.- In 1H2024, the Group made extensive efforts to integrate eucatech AG, a German company acquired last year, into its operations and reorganize its production lines, and expects eucatech AG to resume production and shipment in Q3.- The Group has been actively registering products of eucatech AG in various countries and regions, and eucaLimus, a coronary drug eluting stent, has already received registration approval in Malaysia.- For the clinical studies of TricValve, patient enrollment has commenced in 13 hospitals in the PRC. In Japan, the Group is working closely with the Pharmaceuticals and Medical Devices Agency (“PMDA”) and the US Food and Drug Administration (“FDA”) to prepare for the clinical trial and registration process.- In May 2024, the Group engaged the main contractor for its largest R&D and manufacturing facility in Hangzhou, which is expected to begin operation in 2027, adding an annual production capacity of 2.4 million product units upon commencement of production.- The Group’s financial position remained strong, as evidenced by the cash and bank balances of US$246.7 million as of June 30, 2024.- The Group expects to maintain a stable dividend policy, demonstrating its confidence in future prospects.HONG KONG, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, today announced its interim results for the six months ended June 30, 2024 (the “Reporting Period”), with revenue and profit for the period attributable to owners of the Company maintained at US$78.9 million and US$18.8 million respectively despite various market challenges.Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “The global economy has been highly volatile in recent years, as a result of factors such as geopolitical tensions and major central banks shifting their monetary policies. Albeit the challenging external environment, we were able to seize the opportunity to implement a series of measures to enhance operational efficiency and integrate the businesses of SJ Medicare, PT Revass and eucatech AG acquired last year into our Group. We believe the investments made in the first half year are crucial to supporting our future sustainable growth.”For the Reporting Period, the Group’s revenue decreased slightly by 3.1% to US$78.9 million, mainly attributable to decline in sales volume in the US due to integration of Cardiovascular Systems, Inc. (“CSI”) into Abbott Laboratories (“Abbott”), and in the PRC market due to on-going impact of anti-corruption campaign, as well as the Group’s termination of distribution of certain third-party products, despite the significant sales growth recorded in APAC, as well as the modest revenue growth in Japan in terms of Japanese Yen. Excluding the impact of the foreign exchange fluctuations, total revenue would have recorded a slight year-on-year increase of 0.6%. Gross profit amounted to US$55.8 million while gross profit margin stood at 70.7%.Despite the decline in revenue and the short-term increase in expenses incurred by the Group’s series of measures to enhance operational efficiency and integrate the businesses acquired in the previous year, the Group maintained a healthy level of net profit for the first half of 2024. It is worth noting that, excluding the operating expenses of the newly acquired businesses, the three core operating expenses, namely selling and distribution expenses, general and administrative expenses and research and development expenses, for the first half of 2024, remained flat against the same period last year. As of June 30, 2024, the Group maintained a strong financial position with cash and bank balances of approximately US$246.7 million, laying a solid foundation to support its growth objective.Robust Balloon Sales in APAC and EMEAThe Group’s proprietary balloon products continued to gain traction worldwide. In the first half of 2024, revenue from the APAC market saw organic growth of a marked 8.6% year-on-year, thanks to strong balloon sales growth in markets such as Malaysia, Hong Kong, India, Vietnam and Singapore. Particularly, the latest generation of scoring balloon, Scoreflex TRIO, recorded a rapid rise in sales since it was launched in Malaysia in early 2024. Together with the additional contribution of US$4.3 million from the SJ Medicare and PT Revass, distributors acquired in South Korea and Indonesia respectively in Q4 2023, the revenue generated from APAC amounted to a total of US$24.0 million, representing a significant increase of 31.0% year-on-year.In addition, mainly attributable to the increase in sales of the Group’s proprietary balloon products in direct sales markets such as Germany, France and Spain, as well as distributor sales markets including Czech Republic and Slovakia, revenue generated from EMEA slightly increased by 1.3% to US$19.2 million, even being partly offset by the termination of distribution agreement with CSI for atherectomy products.During the first half of 2024, Scoreflex TRIO continued to drive revenue generated from Japan, the Group’s largest single-country market, in terms of Japanese Yen, achieving an 8.1% increase year-on-year.Integrating Newly Acquired Business to Drive Future GrowthFollowing the acquisition of eucatech AG in November 2023, extensive efforts were made to integrate eucatech AG into the Group’s operation and reorganize production lines. The Group has been actively registering eucatech AG’s four products, namely eucaLimus, Support C, Resistant, and VITUS, in various countries and regions to avail those products via the Group’s own sales network to physicians and patients in different markets. In the first half of 2024, eucaLimus was granted registration approval in Malaysia, one of the Group’s direct sales markets. Registration applications for eucatech AG’s products have also been submitted to relevant regulatory bodies in Hong Kong, Malaysia, Switzerland, Italy and Saudi Arabia and are pending approval. The Group also promoted eucatech AG’s products at major conferences including EuroPCR, as well as educated distributors about these offerings so that sales could be ramped up smoothly once the products become available.In April 2024, the Group supported eucatech AG’s on-site Medical Device Directive (“MDD”) and Medical Device Regulation (“MDR”) surveillance audit, as such, was able to extend the CE Mark expiration dates for their 4 products under the MDD framework. All these efforts are expected to see eucatech AG resume production and shipment in the third quarter of the year.Relentless Drive to Translate Innovations into Thriving Product LinesAs of June 30, 2024, OrbusNeich had an aggregate of over 50 approved products. The Group has maintained a steadfast commitment to translating its R&D efforts into commercially successful products. To date, the Group achieved major milestones, including:- Obtaining NMPA approval for Teleport Neuro, FDA approval for Teleport XT and JADE PLUS 14/18/35 OTW, CE Mark for Sapphire ULTRA and Sapphire NC ULTRA;- Submission of registration applications to the NMPA for its Guiding Catheter;- Completion of the clinical trial patient enrollment for Scoreflex TRIO in the PRC, with the NMPA application expected to be submitted in Q3 2024;- Preparation for the Sapphire 3 clinical trial in the US, with enrollment scheduled to begin in Q3 2024.Alongside these regulatory and commercialization efforts, the Group continued to invest in new pipeline products, such as the Corepass modular microcatheter, support catheter and the JADE Plus. Registration applications for these innovative offerings are planned for submission to various authorities in 2024.Meanwhile, the joint venture OrbusNeich P&F made significant efforts to advance the clinical studies of TricValve in two major Asia Pacific markets. Patient enrollment has commenced in the PRC for its clinical trial, and the clinical trial and registration process in Japan is being prepared in close collaboration with the PMDA and the FDA.Boosting Production Capacity through Rigorous Quality Processes and Operational ExcellenceThe Group has always prioritized product quality, which is ensured by a robust quality management system. During the Reporting Period, various sites successfully passed audits conducted by various regulatory and notifying bodies. Furthermore, the Group remains committed to enhancing operational efficiency and reducing production costs by continually optimizing manufacturing processes, work-in-progress inventory levels, and employee productivity. To meet future production needs, the Group will construct its largest R&D and manufacturing facility in Hangzhou, the PRC, for which it engaged the main contractor in May 2024 and which is expected to begin operation in 2027, adding an annual production capacity of 2.4 million units of products upon commencement of production.Mr. Chien concluded: “Looking ahead, as new sales strategies are being executed in the PRC and the US markets, we expect these key geographies will regain growth momentum in second half of the year. Meanwhile, OrbusNeich has maintained active efforts to expand our market presence. On the product front, we are leveraging our comprehensive sales network and brand recognition to market innovative endovascular intervention products to enhance the solutions we provide to the physicians. New products from eucatech AG which is expected to resume production soon will also contribute to improved profitability. We are also actively identifying M&A opportunities that align with our strategic priorities and position us for sustainable growth. Despite the first-half headwinds, we remain optimistic about restoring growth momentum soon and expect to maintain a stable dividend policy for shareholders based on our robust financial position.”- End -About OrbusNeich Medical Group Holdings LimitedOrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It is also actively expanding into neuro vascular intervention and structural heart disease. As of June 30, 2024, OrbusNeich has more than 230 granted patents and published patent applications worldwide. Its in-house R&D team has more than two decades of product development experience and has developed world-leading proprietary technologies.For more information, please visit the Group’s official website: https://orbusneich.com/. Copyright 2024 ACN Newswire via SeaPRwire.com.

業聚醫療2024年上半年純利達1,880萬美元

業績亮點:- 收入及純利分別達78.9百萬美元及18.8百萬美元。- 亞太地區市場收入顯著增長31.0%,主要受惠於內部增長,以及於2023年第四季收購的韓國分銷商SJ Medicare及印尼分銷商PT Revass所帶來的貢獻。- 自有產品的總銷量維持在717,000件。- 於2024年上半年,集團將去年收購的德國公司eucatech AG與集團的營運整合,並重組其生產線,預期eucatech AG將於第三季度恢復生產及出貨。- 集團一直積極在多個國家及地區註冊eucatech AG的產品,其中,冠狀動脈藥物洗脫支架eucaLimus已於馬來西亞獲批准註冊。- TricValve的臨床研究方面,OrbusNeich P&F已為該產品於中國13家醫院展開病人入組。在日本,集團正與醫藥品醫療機器綜合機構(「PMDA」)及美國食品藥品監督管理局(「FDA」)緊密合作,為該產品的臨床測試及註冊程序作準備。- 於2024年5月,集團已為旗下位於杭州的最大研發及生產設施委聘總承建商,預期於2027年投產,屆時將為集團的年產能增加240萬件產品。- 於2024年6月30日,集團的財務狀況穩健,現金及銀行結餘達246.7百萬美元。- 集團預期維持穩定的股息政策,顯示對前景充滿信心。香港, 2024年8月16日 - (亞太商訊 via SeaPRwire.com) – 專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司(「業聚醫療」或「集團」;股份代號:6929)今天宣佈截至2024年6月30日止六個月(「報告期」)的中期業績。儘管面對不同的市場挑戰,集團的收入及本公司擁有人應佔期內利潤仍分別保持於78.9百萬美元及18.8百萬美元的水平。業聚醫療董事長、執行董事兼行政總裁錢永勛先生表示:「由於地緣政治局勢緊張及主要央行貨幣政策轉變等因素,全球經濟近年一直非常動盪。儘管外圍環境充滿挑戰,我們仍能把握契機,採取一系列措施提高營運效率,並將去年收購的SJ Medicare、PT Revass 及eucatech AG與集團的業務整合。我們相信,上半年所作的投資對於支持集團未來可持續增長至關重要。」報告期內,儘管亞太地區的銷售錄得大幅增長,以及日本市場以日圓計價收入也達到溫和增長,然而,由於Abbott Laboratories(「雅培」)對Cardiovascular Systems, Inc. (「CSI」)進行整合令美國銷量下跌、中國市場受到反腐運動持續影響,以及集團終止分銷若干第三方產品,集團的收入微跌3.1%至78.9百萬美元。若撇除外匯波動影響,總收入按年微升0.6%。毛利為55.8百萬美元,毛利率達70.7%。儘管收入下降,以及集團為提高營運效率及整合去年收購的業務而採取了一系列措施,導致短期開支增加,但2024年上半年的純利仍維持穩健。值得一提的是,若撇除新收購業務的營運開支,2024年上半年的銷售及分銷開支、一般及行政開支及研發開支三項核心營運開支的水平,事實上與去年同期相若。截至2024年6月30日,集團的財務狀況穩健,現金及銀行結餘達約246.7百萬美元,為支持集團達致增長目標奠定堅實基礎。亞太地區及歐洲、中東及非洲地區球囊銷售表現強勁集團的自有球囊產品繼續深受全球歡迎。2024年上半年,有賴馬來西亞、香港、印度、越南及新加坡等市場的球囊銷售額增長強勁,帶動亞太地區市場收入取得8.6%的自然增長。特別是最新一代刻痕球囊Scoreflex TRIO,自2024年初在馬來西亞推出以來,銷量迅速攀升。這加上集團在2023年第四季收購的韓國分銷商SJ Medicare及印尼分銷商PT Revass在期內帶來4.3百萬美元的額外收入貢獻,推動亞太地區的總收入同比大升31.0%至24.0百萬美元。此外,主要受惠於集團的自有球囊產品在直銷市場,如德國、法國及西班牙,以及分銷市場,如捷克及斯洛伐克的銷量有所增加,即使集團與CSI終止有關旋磨產品的分銷協議抵銷了部分收入升幅,來自歐洲、中東及非洲的收入仍增加1.3%至19.2百萬美元。2024年上半年,Scoreflex TRIO繼續推動集團最大單一地域市場――日本的收入增長,按日圓計價,較去年同比增長8.1%。整合新收購業務 推動未來增長繼2023年11月收購eucatech AG後,集團積極投入各項工作,致力將eucatech AG整合至集團營運,並重組其生產線。集團積極在多個國家及地區註冊eucatech AG旗下eucaLimus、Support C、Resistant及VITUS四款產品,以便透過集團自身的銷售網絡,向不同市場的醫生及患者提供這些產品。2024年上半年,eucaLimus於集團的直銷市場馬來西亞獲批准註冊,而eucatech AG其他產品的註冊申請亦已提交予香港、馬來西亞、瑞士、意大利及沙特阿拉伯的相關監管機構,正等待批准。此外,為穩步提升eucatech AG旗下產品上市後的銷量,集團於EuroPCR等重要會議上進行推廣,並向分銷商提供有關產品的資訊。2024年4月,集團為eucatech AG接受關於醫療器械指令(「MDD」)及醫療器械條例(「MDR」)現場監督審核提供支援,從而在MDD框架下延長上述四款產品的CE標誌到期日。通過以上舉措,eucatech AG有望於今年第三季恢復生產及出貨。致力將創新理念轉化為豐富的產品線截至2024年6月30日,業聚醫療共有逾50款獲批產品。集團一直堅持將研發成果轉化為成功商業化的產品,至今已實現多個重大里程碑,包括:- Teleport Neuro獲得NMPA批准;Teleport XT、JADE PLUS 14/18/35 OTW獲FDA批准;Sapphire ULTRA及Sapphire NC ULTRA取得CE標誌;- 向國家藥監局提交導引導管註冊申請;- Scoreflex TRIO在中國的臨床測試病人入組完成,預計將於2024年第三季向國家藥監局提交申請;- 現正為Sapphire 3美國臨床測試做準備,並計劃於2024年第三季在美國開始進行病人入組。除上述監管及商業化工作外,集團亦繼續投資於新產品管線,例如Corepass模組化微導管、支撐導管及JADE Plus,並預計於2024年向各監管機構提交該三種創新產品的註冊申請。與此同時,合資企業OrbusNeich P&F於兩個主要亞太區市場大力推進TricValve臨床研究。在中國,臨床測試已展開病人入組;而在日本,OrbusNeich P&F與PMDA及FDA緊密合作,準備於日本進行TricValve臨床測試及註冊。透過嚴格質量控制及卓越運營流程提升產能集團重視產品質量,並以嚴格的質量管理系統把關。報告期內,集團多個生產基地順利通過了不同監管機構及認證機構的審核。此外,集團亦持續優化生產流程、半成品庫存及人員的生產力,以提升營運效率及降低生產成本。為滿足未來生產所需,集團於中國杭州市興建旗下最大的研發生產設施,並已於2024年5月委聘總承建商,預期於2027年投產,屆時將為集團的年產能增加240萬件產品。 錢先生總結道:「展望未來,我們預期集團在中國及美國兩大主要地域市場實施新銷售策略後,此兩大巿場將能在今年下半年重拾增長動力。與此同時,我們亦會繼續拓展市場據點。產品方面,我們會利用完善的銷售網絡及品牌知名度,推廣創新的血管介入產品, 致力為醫生提供更佳的解決方案。而隨著eucatech AG即將恢復生產,其新增至集團的產品亦有助加強我們的盈利能力。我們亦正積極物色符合集團策略重點的併購機會,以進一步推動集團可持續增長。儘管上半年面臨諸多挑戰,我們仍對迅速恢復增長勢頭保持樂觀,並期望在穩健的財務基礎上,為股東維持穩定的股息政策。」— 完 —關於業聚醫療集團控股有限公司業聚醫療是一家主要的全球醫療器械製造商,專門生產用於經皮冠狀動脉介入治療(PCI)及經皮腔內血管成形術(PTA)的介入器械。業聚醫療的總部位於中國香港,產品銷往全球超過70個國家和地區。集團亦積極將業務擴展至神經血管介入及結構性心臟病領域。截至2024年6月30日,業聚醫療已於全球擁有超過230項授權專利及已公佈專利申請,其內部研發團隊擁有逾20年的產品開發經驗,並已開發出世界領先的專有技術。如需瞭解更多詳情,請訪問集團官網:https://orbusneich.com/ Copyright 2024 亞太商訊 via SeaPRwire.com.

康哲藥業(00867)發佈2024年中期業績:營業額和利潤環比均穩步提升

香港, 2024年8月16日 - (亞太商訊 via SeaPRwire.com) – 深圳 - 2024年8月15日,康哲藥業發佈2024年中期業績公告,整體營業額和期間利潤環比去年下半年穩步提升。2024年上半年實現營收36.11億元,同比下降21.7%,環比增長6.1%;若全按藥品銷售收入計算營收42.88億元,同比下降22.6%,環比增長8.9%;其中,非國採獨家產品及創新產品合計銷售收入為人民幣24.05億元,佔全按藥品銷售收入計算營業額的56.1%。實現淨利潤9.03億元,同比下降52.8%,環比大幅增長92.8%。2024年,正值康哲藥業創新產品商業化的開局之年,也是國家帶量採購(國採)對其業績影響得以釋放的關鍵節點。因黛力新進入第七批國採目錄,於2022年11月執行;波依定和優思弗進入第八批國採目錄,於2023年7月開始執行;且三款原研藥品均未中標,對公司經營業績帶來負面影響。2024年上半年,公司整體業績環比去年下半年呈現增長態勢,標志著康哲藥業已基本消化國採影響,成功邁入由非國採獨家產品和創新產品驅動業務增長的「新產品時代」。隨著萊芙蘭(亞甲藍腸溶緩釋片)於今年6月獲批上市,美泰彤(甲氨蝶呤註射液)增加成人活動性類風濕關節炎適應症於7月獲批上市,康哲藥業處於商業化階段的創新藥組合已擴充至5款產品(含6項適應症),並有豐富的差異化創新管線儲備。聚創新之能,乘發展之勢,康哲藥業正以更健康的產品結構全面塑造發展新動能,進一步迎接高質量發展新周期。「合作+自主」雙擎研發模式驅動管線量質齊升,加速創新科研成果轉化深厚的創新藥研發管線是康哲藥業長期發展的重要驅動力。公司以堅持滿足臨床未盡之需,解决患者用藥之困為創新目的,以「合作研發+自主研發」雙擎驅動,不斷佈局FIC(全球首創)與BIC(同類最佳)創新產品,並提升研究與臨床開發的能力與效率,實現醫藥科研成果社會和商業價值的快速轉化。截至目前,康哲藥業中國獲批上市的創新產品組合已擴充至5款產品(含6項適應症),其中4款創新藥(維圖可、益路取、美泰彤-銀屑病適應症、維福瑞)已獲納入國家醫保目錄,並進入規模化臨床應用;並新增創新藥萊芙蘭、美泰彤(類風濕關節炎)在中國獲批上市。康哲藥業亦穩步推進創新產品臨床開發相關工作。目前,德昔度司他片正處於中國NDA審評中;合計約10個項目即將開展/正在推進以註冊性隨機對照試驗(RCT)為主的臨床試驗。同時,公司不斷强化基礎研究和自主創新能力,目前已順利推進10余項自主研究項目,其中三款創新藥(VEGFA+ANG2四價雙特異性抗體、高選擇性TYK2抑制劑CMS-D001片、及GnRH受體拮抗劑CMS-D002膠囊)已進入臨床開發階段。此外,公司創新管線不斷擴充。今年3月,康哲藥業與Incyte再度達成合作,獲得選擇性小分子口服JAK1抑制劑povorcitinib在中國大陸、香港、澳門、台灣地區及東南亞11國等國家/地區的研究、開發、註冊及商業化產品的獨家許可權利,進一步豐富公司在白癜風和其他免疫介導皮膚病治療領域的產品組合。接下來,康哲藥業每年將持續以更高效率、更可控成本源源不斷產出創新產品,加速創新價值釋放,通過以非國採獨家產品和創新產品為主導的健康產品結構,迎接高質量、可持續的業績增長。成功的商業化體系,高效協同創新產品臨床價值釋放深耕專科領域32年,成功的商業化能力是康哲藥業核心競爭力之一。通過持續强化與整合「開放式商業化平台」,已實現心腦血管/消化、皮膚、眼科三大獨立運營業務深入發展,並在關聯領域擴張邊界;已建立强執行力、高素質的專業推廣團隊、廣泛的渠道與資源覆蓋,為公司創新產品實現快速市場准入與品牌塑造奠定了堅實基礎。康哲藥業四款已進入大規模臨床應用的創新藥,覆蓋中樞神經、皮膚、腎內、消化系統等相關疾病領域,與原有品種在團隊和渠道等方面協同增效發展。同時,憑藉已獲納入國家醫保目錄的契機,公司正大力推動醫院開發、品牌力建設,真實世界研究,及圍繞醫學驅動的學術推廣工作;並結合患者援助及科普教育項目,提升患者對創新藥可及性,推動創新產品臨床價值釋放。皮膚醫美業務「康哲美麗」以皮膚治療處方產品為核心,輕醫美產品和皮膚學級護膚品為延展,不斷完善皮膚治療、皮膚護理和醫療美容全生命周期皮膚健康管理平台。在皮膚處方藥臨床開發方面,已完成磷酸蘆可替尼乳膏白癜風適應症的關鍵真實世界研究,正在推進中國大陸註冊上市申請工作。同時,持續補充再生類輕醫美產品矩陣,其中童顔針的中國醫療器械註冊申請已於報告期內獲受理;並新獲三款處於中國註冊性臨床階段的再生類輕醫美產品,「少女針」、「微晶瓷」、及脫細胞基質植入劑的中國商業化獨佔許可權利。業績公告顯示,截至6月底,康哲藥業推廣網絡覆蓋中國超5.5萬家醫院及醫療機構,約28萬家終端零售藥店。通過在心腦血管、消化、中樞神經系統、腎內科、眼科、皮膚科等專科領域優勢積累,康哲藥業穩步釋放專科業務規模效益,高築業務競爭壁壘,持續構建自身優勢專科治療領域護城河,為多款創新產品和獨家品種的商業化帶來廣闊前景。擘畫國際化佈局,為增量市場蓄勢聚力東南亞業務公司「康聯達健康」整合集團化優勢資源,將康哲藥業在中國市場的成功經驗、全球優質產品和創新技術資源外溢共享到東南亞,加速完善東南亞業務「研產銷」一體化的開放式平台,為中國和全球藥企高質量「出海」戰略賦能,也為康哲藥業打開更大的增量發展空間。截至6月底,康聯達健康已建立有競爭力的產品組合,擁有十餘款差異化品種,覆蓋腫瘤、中樞神經、自免、皮膚科、眼科等疾病領域。康聯達健康正加速推進多款創新儲備產品在東南亞各國的上市申請和註冊相關工作,如蘆可替尼乳膏、亞甲藍腸溶緩釋片、地西泮鼻噴霧劑等;並與君實生物正共同推動特瑞普利單抗(抗PD-1單抗)於東南亞多國的註冊進程,以期儘快惠及當地腫瘤患者。去年12月,康哲藥業、康聯達健康携手康龍化成等共同促成了新加坡生產工廠的收購。今年,各方正持續有序推進該生產工廠的設備檢測、質量核查、生產質量體系認證等系列工作,旨在加速CDMO業務進程,並進一步優化集團海外供應鏈和生產能力。此佈局將助力康哲藥業未來與全球合作夥伴開展更多產業間合作,共同構建共贏互惠的開放式醫療創新生態。結語自1992年創立至今,康哲藥業順延行業發展脉絡,以前瞻性視野成功推動了三次意義重大的戰略轉型。公司起步於進口原研藥品的代理,逐步發展至控制原研/獨家成熟產品權利,再到實現了全面創新轉型,每一步都踏在產業發展迭代的節奏中。征程萬里風正勁,康哲藥業目標如炬,不斷壘築發展厚度,構建穿越周期的韌性。如今,隨著國採對公司業績的影響逐步釋放,康哲藥業已煥然一新,在擁抱階段性創新成果的同時,以更充分的準備去迎接未來更長遠、更健康的發展。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化,把控產品全生命周期管理的開放式平台型企業,致力於提供有競爭力的產品和服務,滿足尚未滿足的醫療需求。康哲藥業專註於全球首創(FIC)及同類最優(BIC)的創新產品,並高效推進創新產品臨床研究開發和商業化進程,賦能科研成果向實踐診療的持續轉化,造福患者。康哲藥業聚焦專科領域,擁有被驗證的商業化能力,廣泛的渠道覆蓋和多疾病領域專家資源,核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展,以鞏固心腦血管/消化業務競爭力,並將皮膚醫美、眼科業務獨立運營,培育專科小領域的大龍頭,提升專科規模效率。同時業務版圖拓展至東南亞市場,著力成為全球藥企進軍東南亞市場的「橋頭堡」,助力康哲藥業高質量持續健康發展。康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣,非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療信息,請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的决定應根據患者的具體情况並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請,不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制,但康哲藥業並無進行任何說明或保證、明述或暗示,或其他表述,對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及本集團的市場機會及業務前景的陳述,該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證,存在已知及未知的風險、不明朗性及難以預知的假設。本集團並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測,本集團對該等第三方聲明及預測不承擔責任。 Copyright 2024 亞太商訊 via SeaPRwire.com.

Overcome Cybersecurity Challenges in the Financial Services Industry at CISO FSI ANZ Online

BRISBANE, AUS, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - CISO FSI ANZ 2024 invites cybersecurity professionals in the Financial Services Industry to join this free virtual event designed to inspire and share intelligence. The online gathering will cover everything from cyber strategy, risk management, governance, program and incident management, leadership, to enabling business growth.CISO FSI ANZ offers a unique opportunity to expand your knowledge and find ways to avoid cyber threats in the FSI industry. Benchmark your strategies with peers and learn how to get buy-in and collaboration in your projects across the board.Key topics include:Strategies to advance your company’s cyber security maturity modelsHow to align cyber risk management with the company's goalsComplying with APRA regulations in Australia and MBIE in New ZealandThe impacts of the privacy act reform in information securitySuccessful practices to mitigate the increase of third-party risksBridging the talent gap by investing in culture, education and trainingNavigating the “AI high” by leveraging its benefits while minimising its risksCISO FSI ANZ is an essential online event for those looking to advance their knowledge and network within the cybersecurity community. Join us on 12 September 2024 at 10 AM AEDT or 12 PM NZT.It’s free! Register now: https://bit.ly/4dpyOUYVisit website: https://ciso-fsi-anz.coriniumintelligence.com/About Corinium IntelligenceCorinium Intelligence is a global leader in providing conferences, events, and content to the information and technology industries. With a focus on fostering collaboration and innovation, Corinium Intelligence brings together industry leaders to share insights, best practices, and strategies for success.Media Contact:Claudia Peixoto, Marketing Managerclaudia.peixoto@coriniumgroup.com Copyright 2024 ACN Newswire via SeaPRwire.com.

Join the Collective Effort to safeguard government and commonwealth entities at CISO Canberra

CANBERA, AUSTRALIA, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - CISO Canberra invites cyber security professionals to explore the critical role of public sector cyber security in protecting the public and driving transformative leadership strategies for delivering the 2023-2030 Australian Cyber Security Strategy.The tech demo exhibition will showcase cutting-edge services and innovations driving change in the cybersecurity landscape. InfoSec leaders will share their strategic insights in no-nonsense talks, providing valuable substance over empty rhetoric.Key themes include:STRENGTH IN UNITY: Building robust shields against cyber threats by navigating the 2023-2030 Australian Cyber Security Strategy to be the most secured nation.AWARENESS, EMPOWERMENT, & COORDINATION: Maturing cyber security culture through collective responsibility and collaborative efforts for enhanced resilience.PROACTIVE GRC MANAGEMENT: Integrating Zero Trust and evaluating risks in supply chains, data and AI to empower decision making at the pace of innovation.MODERNISING THREAT DETECTION & RESPONSE: Embracing cutting-edge technologies and strategies to advance security, integrity and resilience capabilities.CISO Canberra 2024 is an essential event for those looking to advance their knowledge and network within the cybersecurity community. Join us at the Canberra Rex Hotel on 14 November 2024 for an event that promises to inspire and empower.Use the code ACNNEWS20 for 20% off the ticket price.Register here: https://bit.ly/4dqzPfbVisit website: https://ciso-bris.coriniumintelligence.com/ About Corinium IntelligenceCorinium Intelligence is a global leader in providing conferences, events, and content to the information and technology industries. With a focus on fostering collaboration and innovation, Corinium Intelligence brings together industry leaders to share insights, best practices, and strategies for success.Media Contact:Claudia Peixoto, Marketing Managerclaudia.peixoto@coriniumgroup.com Copyright 2024 ACN Newswire via SeaPRwire.com.

China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023

SHENZHEN, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - On August 15, 2024, China Medical System Holdings Limited (“CMS” or the “Company”) released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. In the case that all medicines were directly sold by the Company, the turnover was RMB4,287.5 million, representing a decrease of 22.6% compared with 1H 2023, an increase of 8.9% compared with 2H 2023; Among which, the total revenue of non-National VBP exclusive products and innovative products was RMB2,404.7 million, accounting for 56.1% of CMS’s revenue in the case that all medicines were directly sold by the Company. Profit for the period was RMB903.4 million, representing a decrease of 52.8% compared with 1H 2023, a substantial increase of 92.8% compared with 2H 2023.The year 2024, not only marks the first year of the commercialization of CMS’s innovative products, but also a crucial point for the release of National Volume Based Procurement (“National VBP”) impact on its financial performance. Deanxit entered the seventh batch of National VBP in November 2022, Plendil and Ursofalk entered the eighth batch of National VBP in July 2023, and none of the three original drugs were selected, which had a negative impact on the Company’s business performance. In 1H 2024, the Company’s overall performance showed a growth trend compared with 2H 2023, indicating that CMS has basically digested the impact of National VBP and successfully entered the "New Product Era" where non-national VBP exclusive products and innovative products drive its growth.With the approval for marketing of LUMEBLUE (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) in June and METOJECT (Methotrexate Injection)’s additional indication of active rheumatoid arthritis (RA) in adults in July this year, CMS's innovative drug portfolio in the commercialization stage has expanded into 5 products (including 6 indications); simultaneously with a rich and differentiated innovative pipeline reserve. Gathering the power of innovation and riding the momentum of development, CMS is comprehensively shaping new drivers for development with a healthier product structure, further opening up a new cycle of quality development.The "Collaborative and In-house" dual-engine R&D model drives the simultaneous improvement in quantity and quality of the pipeline, accelerating the transformation of innovative biotechnologyA profound innovative drug R&D pipeline is an important driving force for the long-term development of CMS. The Company adheres to the purpose of innovation for meeting the unmet clinical needs and solving the difficulties of patient medication, and promotes innovation development through a two-wheel drive of “Collaborative R&D and In-house R&D”, continuously deploying FIC (first-in-class) and BIC (best-in-class) innovative products, and enhancing the capabilities and efficiency of research and clinical development to achieve a rapid transformation of scientific outcomes into social and commercial values.As of now, CMS's innovative product portfolio approved for marketing in China has been expanded into 5 products (including 6 indications), among which, 4 innovative drugs (VALTOCO, ILUMETRI, METOJECT - psoriasis indication, VELPHORO) have been included in the National Reimbursement Drug List (NRDL) and entered large-scale clinical application; also, CMS newly added LUMEBLUE and METOJECT (RA), for being approved for marketing in China recently.CMS has also steadily advanced the clinical development of innovative products. Currently, Desidustat Tablets is under NDA review in China; Also, a total of about 10 projects have been prepared/launched for their registrational clinical trials, mainly randomized controlled trials (RCT).At the same time, the Company had continued to strengthen basic research and independent innovation capabilities, and successfully promoted more than 10 in-house R&D projects, among which, three innovative drugs (VEGFA/ANG2 Tetravalent Bispecific Antibody, Highly Selective TYK2 Inhibitor CMS-D001 Tablets, and GnRH Receptor Antagonist CMS-D002 Capsules) have entered the clinical development stage.In addition, the Company’s innovative pipeline has continued to expand. CMS Skinhealth collaborated with Incyte once again, and has obtained exclusive license to research, develop, register and commercialize povorcitinib, a selective oral small-molecule JAK1 inhibitor, in countries/territories including Mainland China, Hong Kong, Macau, Taiwan Region and 11 Southeast Asian countries. This further enriched the product portfolio of CMS Skinhealth in the treatment of vitiligo and other immune-mediated dermatology diseases.Subsequently, CMS will continue to produce innovative products with higher efficiency and more controllable costs every year, accelerating the release of innovative value and embracing quality and sustainable performance growth through a healthy product structure dominated by non-National VBP exclusive products and innovative products.Successful commercialization system releases the clinical value of innovative products in an efficient and collaborative mannerAfter 32 years of deep cultivation in specialty therapeutical fields, successful commercialization capability is one of CMS’s core competitiveness. By continuously reinforcing and integrating its commercialization platform, it has achieved in-depth development of its three major business segments including cardio-cerebrovascular/gastroenterology, dermatology, and ophthalmology, and expanded its boundaries in related fields. Additionally, the Company established a highly qualified, professional promotion team with strong execution, as well as extensive channel and resource coverage, which has laid a solid foundation for the rapid market entry and brand building of its innovative products.Four innovative drugs of CMS have entered large-scale clinical applications, covering various disease fields such as central nervous system, dermatology, nephrology, and gastroenterology, and developed synergistically with the existing marketed products in promotion team and channels. Meanwhile, leveraging on the opportunity of being included in the NRDL, CMS is advancing hospital development, brand building, real world studies and medically-driven academic promotion. CMS is improving patients’ accessibility to innovative drugs with the help of patient aid and disease knowledge popularization programs, promoting the release of products’ clinical value.The Dermatology and Medical Aesthetic Business "CMS Skinhealth" regards dermatology prescription products as its core, and extends to light medical aesthetic products and dermatology-grade skincare products, continuously improving the construction of a full life-cycle skin-health management platform covering dermatological treatment, skincare, and medical aesthetics through internal development and external collaboration. In terms of clinical development of dermatology prescription drugs, CMS has completed the Pivotal Real World Study for ruxolibinib cream in vitiligo, and is advancing the registration application process in Mainland China. At the same time, it has continuously complemented the regenerative light medical aesthetic portfolio, among which the China’s medical device registration application of the Poly-L-lactic Acid Microparticle Filler Injection has been accepted by the NMPA during the Reporting Period; and the Company has newly obtained exclusive licenses of three regenerative light medical aesthetic products (Polycaprolactone Microsphere Gel for Injection, Calcium Hydroxylapatite Microsphere Gel for Injection, and Decellularized Extracellular Matrix Implant), which are currently under the registrational clinical trial stage in China.The results announcement shows that, as of the end of June, the promotion network of CMS has covered over 55,000 hospitals and medical institutions, and approximately 280 thousand retail pharmacies in China.Leveraging the accumulated advantages in cardio-cerebrovascular, gastroenterology, central nervous system, nephrology, ophthalmology, dermatology and other specialty therapeutical fields, CMS steadily releases the scale effect of its specialty businesses, and builds high competition barriers, creating broad commercial potential for its innovative products and exclusive products.Drawing up the internationalization layout to gather momentum for the incremental marketIntegrating the advantageous resources of the Company, its Southeast Asia business “Rxilient Health”, shares and expands the successful experience of CMS gained from the China market, as well as global quality products and innovative technological resources, into the Southeast Asia market. This accelerates the improvement of the platform integrating “R&D, manufacture, and commercialization” of the Southeast Asia business, empowering Chinese and global pharmaceutical companies to implement the “overseas development” strategy, and also opening up a larger space for incremental development opportunities for CMS.As of the end of June, Rxilient Health has established a competitive product portfolio with more than ten differentiated products, covering therapeutic areas such as oncology, central nervous system, autoimmune, dermatology, and ophthalmology, etc. Rxilient Health is accelerating the relevant work on the market registration processes in Southeast Asian countries for innovative pipeline products, such as ruxolitinib cream, Methylthioninium Chloride Enteric-coated Sustained-release Tablets, and Diazepam Nasal Spray, etc. Furthermore, Rxilient Health collaborated with Junshi Biosciences to promote the registration process of toripalimab (anti-PD-1 monoclonal antibody) in multiple countries in Southeast Asia, aiming to benefit local cancer patients as soon as possible.In December last year, the Company and Rxilient Health joined hands with Pharmaron and other partners to complete the purchase of the Singapore manufacturing plant. This year, all relevant parties have been orderly advancing a series of work for the Singapore manufacturing plant, including equipment testing, quality verification, and production quality system certification, etc., so as to accelerate the CDMO business development, and to optimize the Company’s overseas supply chain and manufacturing capabilities. The business layout will further facilitate more inter-industry cooperation between CMS and global partners in the future, thus jointly building a win-win medical innovation ecosystem with mutual benefits.ConclusionSince its establishment in 1992, CMS has followed the development pattern of the industry and has promoted three significant strategic transformations successfully with a forward-looking vision. The Company started as an agent of imported original drugs, gradually developed to control the rights of original/exclusive products, and then achieved a comprehensive innovative transformation. Each step of the transformation is in sync with the industry development trends. CMS steadily aims towards the ultimate goal, and constantly builds up its strength and resilience to persist through the industry development cycle. With the gradual release of the impact of national VBP on its financial performance, CMS has been transforming into a brand-new company. While embracing the innovation achievements in each stage, CMS is fully prepared for a sustainable and healthier development in the future.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactChina Medical System Holdings Ltd.CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.

LI NING: Adhered to the Core Strategy of ‘Single Brand, Multi-categories, Diversified Channels’

FINANCIAL HIGHLIGHTS- In the first half of the year, the Group recorded the following operating results:  – Revenue rose by 2.3% to RMB14,345 million; gross profit margin rose by 1.6 percentage points to 50.4%  – Net operating cash inflow increased by 40.6% to RMB2,730 million  – Net profit attributable to equity holders of the Company was RMB1,952 million with net profit margin of 13.6%, and EBITDA margin was 24.0%- Working capital remained at a healthy level:  – The percentage of gross average working capital to revenue was 7.1%  – The cash conversion cycle was 31 days, representing an increase of 1 day as compared to the same period last year- The Board resolved to declare an interim dividend of RMB37.75 cents per ordinary share of the Company issued or to be issued upon conversion of convertible securities for the six months ended 30 June 2024.OPERATIONAL HIGHLIGHTS- The retail sell-through for the overall platform decreased by low-single-digit, including online and offline channels- Channel inventory increased by mid-single-digit comparing to the same period last year. The inventory turnover and ageing structure remained at a healthy level- Offline channel new product sell-through decreased by mid-single-digitHONG KONG, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - Li Ning Company Limited (stock codes: 2331 (HKD counter) and 82331 (RMB counter)) announces today its 2024 interim results for the six months ended 30 June 2024.Financial ResultsIn the first half of 2024, China’s economy demonstrated an orderly recovery, with favorable national policies continuously injecting vitality into the market. Against the backdrop of the rising public health awareness, numerous international and national events have spurred public’s enthusiasm for sports. Currently, overall consumer confidence still has room for recovery, and the market is in a gradual and positive adjustment phase.Leveraging the brand’s professional sports background, the Group maximizes its insights into the sports industry, understanding of sports categories, and technological innovation capabilities, concentrating on five core categories of running, basketball, fitness, badminton, and sports casual during the Reporting Period. Through continuous research and development (“R&D”) investment and technological innovation, the Group consistently enhances product capabilities, optimizes consumer experience, and ensures sustainable development in the long run while expanding the Group’s business.In the first half of 2024, the Group’s overall performance remained stable with pragmatic growth. During the Reporting Period, revenue amounted to RMB14,345 million, representing an increase of 2.3% as compared to the corresponding period of 2023 (2023 H1: RMB14,019 million). Gross profit increased by 5.8% from RMB 6,839 million in the same period of 2023 to RMB 7,236 million, and the overall gross profit margin was 50.4% (2023 H1:48.8%), the gross profit margin increased by 1.6 percentage points as compared to the corresponding period of last year. Basic earnings per share was RMB75.80 cents (2023 H1: RMB80.63 cents). The Board resolved to declare an interim dividend of RMB37.75 cents (2023 H1: RMB36.20 cents) per ordinary share of the Company issued or to be issued upon conversion of convertible securities for the six months ended 30 June 2024. The interim dividend payout ratio is 50%.In terms of cash flow management, the Group's net cash generated from operating activities during the Reporting Period amounted to RMB2,730 million (2023 H1: RMB1,942 million). As at 30 June 2024, cash and cash equivalents (including cash at banks and in hand, and fixed term deposits with original maturity of no more than three months) amounted to RMB6,147 million, representing a net increase of RMB703 million, as compared with the position as at 31 December 2023. Adding back the amount recorded as fixed-term deposits held at banks, cash balance amounted to RMB17,558 million, which represented a net decrease of RMB417 million as compared to 31 December 2023. During the period, revenue increased year-on-year while the efficiency of settlement remained stable, which, in conjunction with the reasonable purchase and payment plan, contributed to the year-on-year increase in net cash generated from operating activities. The Group will continue to place extra emphasis on its cash flow management to ensure stable development of the Group in the long run.Operational SummaryDuring the Reporting Period, the Group adhered to the core strategy of “Single Brand, Multi-categories, Diversified Channels” focusing on seven major business transformation tracks and continuously strengthening its sports genes to establish a clear professional sports brand positioning. Meanwhile, the Group was efficiently empowered in supply chain management, logistics platform, channel expansion and store upgrading, jointly building a solid foundation for the overall sales of the Group.In terms of technological innovation, in May 2024, the Group successfully held a technology conference with the theme of “In My Name, Tech LI-NING” , which demonstrated that the Group has built two key pillars of product development and innovation consisting of technology R&D and sports science research through long-term accumulation of technological innovation. At the conference, the Group presented its six innovative technologies of “Carbon Core” , “Dual-Stage Assist Curves”, “Super Jiang” , “GCU”, “Super BOOM” and “Extreme Boom Fiber” , and also unveiled three new innovations for the first time: the running shoes of “Shadow 3”, the premium racing shoes of “Dragonflight” and dual-vent nanotechnology for rainstorm protection.In terms of professional products and marketing, the Group continued to focus on the five core categories of running, basketball, badminton, fitness and sports casual, and continued to make efforts in the innovation in sports technology. At the same time, the Group also actively integrated with sports fashion culture, launched sports products with both technology and fashion attributes and continuously enhanced the core competitiveness of products. In addition, the Group actively deployed universal marketing to enhance consumers’ awareness of the Group’s products, continuously enhance brand influence and expand its consumer base.In the midst of a great year for sports, the Group launched a campaign theme “In My Name” , to encourage everyone to engage in sports activities and create their own highlight moments. Through delivering the brand proposition and spirit and telling stories of the athletes from the national gold medal team, top athletes in various categories and sports KOLs, as well as overall demonstrating Li Ning’s technological strength, launching theme series products and creating atmosphere for themes at stores, the Group reinforces the professional brand image of LI-NING, realizes the whole chain from brand proposition to product experience, and deeply connects the brand with each consumer.In terms of supply chain management, the Group constructed an all-round and high-efficiency supply chain ecosystem. It not only deeply explored and expanded high-quality supplier resources for high-end sports and outdoor products to form a strong supplier matrix, but also flexibly responded to market changes with a flexible supply strategy as the core.In terms of logistics management, the Group adopted refined logistics plan management, customized strategies based on the characteristics of the business divisions, and optimized the process of goods warehousing and delivery. Meanwhile, the logistics informationization platform empowered distributors to share information in real time, improved the efficiency of store distribution, and further improved the quality of logistics services.In terms of channel expansion and image upgrading, the Group actively optimized its channel layout, consolidated and expanded its competitive advantage in the high-end market by closing low-efficiency stores and strengthening the renovation and expansion of premium stores. Meanwhile, the active development of emerging markets, the new upgrading of the 9th generation stores, and the successful establishment of premium outlets further enhanced the brand image and market influence. In order to create an immersive experience of key events, 4,238 stores introduced key visual display designs featuring “In My Name” themes and core sports resources in the first half of the year, further enhancing consumers’ visual experience and brand awareness.As of 30 June 2024, the number of conventional stores, flagship stores, China LI-NING stores, LI-NING 1990 stores, factory outlets and brand stores under LI-NING brand (including LI-NING Core Brand and LI-NING YOUNG) amounted to 7,677, representing a net increase of 9 Point-of-sale (“POS”) as compared to 31 December 2023. The number of distributors was 44 (including sales channels of China LI-NING stores), representing a net decrease of 2 as compared to 31 December 2023, demonstrating the Group’s precision and efficiency in channel layout.In terms of retail operation, in the first half of the year, the Group deepened the innovation and practice of the single-store operating model to effectively promote the comprehensive implementation of retail operation standards. The store management efficiency has been significantly improved through the comprehensive promotion of its retail end sales planning system and the implementation of the system in core stores.In terms of new retail business, the Group strengthened community operations and content creation through digital transformation to achieve efficient conversion of private traffic, effectively improving sales and conversion efficiency. In addition, the Group actively explored diversified business models, including attracting traffic through social platforms such as Douyin and online business cooperation with core channels, constantly injecting new momentum into store sales, increasing the proportion of out-of-store sales in stores, and further enhancing the operating efficiency of stores.In respect of the e-commerce operation, the e-commerce of Li Ning continued to focus on breakthroughs in professional functional products, especially achieving rapid growth in the field of running shoes, while professional basketball shoe products also consolidated its market leading position. In addition, in terms of online exclusive IP, the Group has successfully created a number of IP that have gained volume and reputation in the industry. During the period, the Group achieved synergistic growth of e-commerce business and retail operation through effective integration and innovative practices across online and offline channels, driving a significant increase in sales performance and further strengthening of market share.In terms of kidswear business, LI-NING YOUNG comprehensively streamlined the youth product matrix, clarified the core competitiveness of clothing and accessories, and improved the footwear product matrix. For marketing, LI-NING YOUNG consolidated its marketing resources and actively explored omni-channel marketing and community operation. By actively cooperating with basketball star Wade to further increase the brand influence. LI-NING YOUNG also actively actively carried out various member community activities and launched new celebrity athlete in-store opening activities to continuously drive store traffic. As at 30 June 2024, the total number of LI-NING YOUNG POS in China amounted to 1,438, representing a net increase of 33 POS since the end of the previous quarter and a net increase of 10 POS since the beginning of this year. The Group will continue to intensely develop its LI-NING YOUNG business, take a product focused approach to upgrade core product technology and design, advance the exploration of market demands and product categorization and strengthen brand promotion, so as to develop LI-NING YOUNG into a leading professional sportswear brand for kids in China.OutlookThe Group will continue to practice its core strategy of “Single Brand, Multi-categories, Diversified Channels”, persistently strengthen its product capabilities and integrate its operational resources to propel the Group towards stable and enduring growth by leveraging the organizational capability as an efficient corporation:– Develop the fundamental business with stability. The Group will continue to amplify the market influence of the LI-NING brand, focusing on the development of its five core categories including running, basketball, fitness, badminton and sports casual. Through investment in research, development and innovation, the Group will achieve continuous upgrading of its product matrix to meet the growing consumer demand for high-quality and personalized sports equipment, thereby reinforcing and expanding the Group’s market leading position in core areas.– Optimize and upgrade the product structure. The Group will further upgrade its diversified product matrix under the single-brand strategy, aligning with the evolving market trends and consumer preferences. By fully leveraging the complementary functions of “China LI-NING” and “LI-NING 1990” in the sports casual sector, and expanding multiple dressing scenarios, the Group will enhance the competitiveness of its brands in diverse scenarios.– Look to the future and seize opportunities to make a breakthrough. The Group will actively explore breakthroughs and take the lead in entering new tracks in sports consumption. By tapping into the huge potential of the women’s, outdoor and youth markets, formulating targeted marketing strategies and launching products that meet the needs of the target groups, the Group aims to make breakthroughs in these new areas.– Optimize market expansion strategy. To achieve comprehensive market coverage, the Group will optimize the allocation of resources to existing high-level markets to improve market efficiency. Concurrently, by actively exploring emerging markets and formulating strategies for overseas markets, the Group strives to achieve significant breakthroughs in overseas markets while keeping a steady and sustainable momentum.Mr. Li Ning, Executive Chairman and Joint CEO of the Group, concluded, “The country's series of in-depth market reform policies will steadily advance, providing the Group with a fair and more vibrant market environment, and opening up broader growth space. The Group will adhere to its established development strategy, rely on the professional sports genes of its brands and continue to launch high-quality sporting products for the public. At the same time, the Group will continue to cultivate the sports market in China, and ride the wave of the Olympics, upholding the spirit of ‘Anything is Possible’, to propel the Chinese sports industry onto the international stage.”- END -About the GroupLi Ning Company Limited is one of the leading sports brand companies in China, mainly operating professional and leisure footwear, apparel, equipment and accessories under the LI-NING brand. Headquartered in Beijing, the Group has brand marketing, research and development, design, manufacturing, distribution and retail capabilities. It has established an extensive retail distribution network and supply chain management system in China. The Group is committed to be the most prominent, stylish, world-leading sports brand from China.In addition to its core LI-NING brand, the Group also manufactures, develops, markets, distributes, sells various sports products which are selfowned by or licensed to the Group, including Double Happiness (table tennis), AIGLE (outdoor sports), Danskin (fashionable fitness products for dance and yoga) and Kason (badminton), which are operated through joint venture/associate with third parties of the Group. Copyright 2024 ACN Newswire via SeaPRwire.com.

Darwinbox revolutionizes Security Bank HCM operations

MANILA, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - Darwinbox, a global leader in providing end-to-end Human Resources Management Systems (HRMS), has significantly transformed the operations of Security Bank Corporation, one of the largest private domestic universal banks in the Philippines and its subsidiaries.This comes as Darwinbox continues to enhance the HR landscape in the Philippines by helping companies optimize their human resources (HR) and improve overall operational efficiency.Security Bank EVP and Chief People Officer, Nerissa Berba, said that Darwinbox, a new-age, enterprise-ready Human Capital Management (HCM) platform, optimized the bank's processes, reduced manual tasks, and enhanced efficiency with streamlined workflows.Security Bank has already observed significant enhancements in its HR processes thanks to Darwinbox. To date, it has automated close to 90 per cent of HR processes, leading to a 67 per cent increase in HR operational efficiency within the first year, which exceeded the initial projection of 30 per cent. Consequently, this has allowed for a 30 per cent improvement in report generation speed and a 75 per cent reduction in the time taken for performance administration ensuring full compliance with policies.Berba further said that Darwinbox met all the bank’s HCM requirements. First, the entire employee lifecycle, from hire-to-retire, can be managed within Darwinbox, allowing the bank to have one system for all its employees’ needs. The Bank has implemented most of the Darwinbox modules, ensuring a consistent experience across the majority of the organization and HR processes.Additionally, the simplicity and user-friendliness of the Darwinbox interface, along with its deep functionality and intuitive mobile app, add significant value to the Bank’s operations. The no-code backend of the highly configurable platform empowers its HR team to tailor processes to the organization’s needs without external consultants.“[Darwinbox] is truly an empowering platform for an enterprise that is customer-first and people-empowered,” Berba said.Security Bank currently provides banking services across the Philippines through a dedicated workforce of nearly 9,000, who deliver the brand’s promise of ‘BetterBanking’.“Our commitment to a future-ready organization hinged on a compelling employee value proposition and a transformative work culture,” Berba said.Meanwhile, Darwinbox, founded in Asia and currently catering to over 950 enterprises worldwide, is actively expanding its presence in the Philippines.The company plans to engage various sectors, utilizing its advanced HR technology to address the diverse needs of organizations in the region. This expansion is in line with Darwinbox's goal to provide businesses with comprehensive and intuitive HR solutions, specifically designed for the unique challenges and opportunities within the Philippine market.Media Contact:Shruti Parmarshruti@bloomingdalepr.comBloomingdale Public Relations Copyright 2024 ACN Newswire via SeaPRwire.com.

李寧:秉承「單品牌、多品類、多渠道」核心戰略

財務業績摘要- 上半年,集團錄得以下經營成果:  – 收入上升2.3%至143.45億元人民幣;毛利率上升1.6個百分點至50.4%  – 經營現金淨流入上升40.6%至27.30億元人民幣  – 本公司權益持有人應佔淨溢利為19.52億元人民幣,淨利率為13.6%,息稅前利潤加折舊及攤銷率為24.0%- 運營資金保持健康水平:  – 平均運營資金總額佔收入比為7.1%  – 現金循環週期為31天,比去年同期增加1天- 董事會決議宣派截至2024年6月30日止六個月之中期股息每股已發行或於可換股證券轉換後將予發行的本公司普通股37.75分人民幣經營業績摘要- 整體零售流水(包括線上及線下)錄得低單位數下降- 渠道庫存同比上升中單位數,庫存周轉與庫齡結構保持在健康水平- 新品線下零售流水錄得中單位數下降香港, 2024年8月16日 - (亞太商訊 via SeaPRwire.com) – 李寧有限公司(香港聯交所股份代號:2331(港幣櫃台)及82331(人民幣櫃台))今天宣佈集團截至2024年6月30日止六個月之中期業績。財務業績2024年上半年,中國經濟展現出有序的復甦態勢,國家政策利好持續為市場注入活力。國民健康意識不斷提升大背景,伴隨多項國際性及國家級體育賽事的到來,催化了民眾運動熱情。目前,整體消費信心仍具恢復空間,市場正在逐步良性調整中。期内,集團依託品牌的專業運動基因,充分發揮運動行業洞察力、運動品類理解力及科技創新研發力,專注於跑步、籃球、健身、羽毛球和運動生活五大核心品類。通過持續的研發投入和科技創新,不斷推動產品力的升級,優化消費者體驗,確保集團在保持業務擴展的同時,實現長期可持續的發展。2024年上半年,集團整體業績平穩,務實發展。期內,集團收入達143.45億元人民幣,較2023年同期上升2.3%(2023年上半年:140.19億元人民幣)。毛利較2023年同期的68.39億元人民幣上升5.8%至72.36億元人民幣,集團整體毛利率為50.4%,較去年同期上升1.6個百分點(2023年上半年:48.8%)。每股基本收益為75.80分人民幣(2023年上半年:80.63分人民幣)。董事會決議宣派截至2024年6月30日止六個月之中期股息,每股已發行或於可換股證券轉換後將予發行的本公司普通股37.75分人民幣(2023年上半年:36.20分人民幣),中期派息比率為50%。現金流管理方面,期內經營活動產生之現金淨額為27.30億元人民幣(2023年上半年:19.42億元人民幣)。於2024年6月30日之現金及等同現金項目(包括銀行現金及手頭現金,以及原到期日不超過三個月的定期存款)為61.47億元人民幣,較2023年12月31日淨增加7.03億元人民幣。加回被記錄在銀行定期存款中的金額,現金餘額為175.58億元人民幣,較2023年12月31日淨減少4.17億元人民幣。期內,收入同比增長,回款效率保持穩定,同時集團合理安排採購及付款計劃,促成經營活動產生之現金淨額同比上升,集團將持續以現金流管理作為重點工作,以保證公司長期穩定的發展。經營概要期內,集團秉持「單品牌、多品類、多渠道」的核心戰略,聚焦七大業務變革賽道,持續強化運動基因,明確品牌專業運動定位,並在供應鏈管理、物流平台、渠道拓展以及門店升級方面高效賦能,共同構築了集團整體銷售的堅實基礎。在科技創新方面,2024年5月,集團成功舉辦「以我為名,科技李寧」主題科技大會,展現集團在長期科技創新積累之下,形成的科技研發及運動科學研究兩大產品研發創新支柱,並展示集團的六大創新科技:「碳核芯」、「最速曲線系統」、「超級弜」、「GCU」、「超級䨻」、「極限䨻絲」,同時亦首次發佈三大創新成果:「絕影3」跑鞋、頂級競速跑鞋「龍雀」、防暴雨雙透納米科技。專業產品與營銷方面,集團繼續專注於跑步、籃球、羽毛球、健身和運動生活五大核心品類,持續在運動科技創新方面發力,同時亦積極與運動潮流文化接軌,推出兼具科技與時尚屬性的運動產品,不斷增強產品的核心競爭力。此外,集團積極佈局全域營銷,加強消費者對集團產品的認知,不斷提升品牌影響力,擴大消費者基礎。體育大年背景下,集團推出「以我為名」主題活動,鼓勵每個人成為運動主角,從傳遞品牌主張和精神,到國家金牌隊運動員、多品類頂級運動員及運動KOL的運動者故事,再到李寧科技實力的整體展現、主題系列產品推出、終端主題氛圍打造,夯實李寧品牌的專業形象,實現從品牌主張到產品體驗的全鏈路,深度連接品牌與每一個消費者。供應鏈管理方面,集團構建了全方位、高效能的供應鏈生態體系,不僅深度挖掘並擴充了高端運動與戶外產品的優質供應商資源,形成強大的供應商矩陣,更以柔性供應策略為核心,靈活應對市場變化。物流管理方面,集團採用精細化物流計劃管理,根據事業部特點定制策略,優化貨品入倉與發貨流程。同時,物流信息化平台賦能經銷商,實時共享信息,提高門店配貨效率,物流服務的質量進一步提升。渠道拓展與形象升級方面,集團積極優化渠道佈局,通過關閉低效店舖並強化優質店舖的改造與拓展,鞏固並擴大在高層級市場的競爭優勢。同時,新興市場的積極開拓,九代店舖的全新升級,以及超級奧萊的成功打造,均進一步提升品牌形象與市場影響力。為了營造沉浸式的關鍵賽事體驗,上半年已有4,238家門店引入「以我為名」主題活動和核心運動資源的關鍵視覺陳列設計,進一步增強消費者的視覺感受和品牌認知。截至2024年6月30日,李寧牌(包含李寧核心品牌及李寧YOUNG)常規店、旗艦店、中國李寧時尚店、LI-NING 1990店、工廠店、品牌集合店的銷售點數量為7,677家,較2023年12月31日淨增加9家;經銷商44家(包括中國李寧時尚店渠道),較2023年12月31日淨减少2家,展現集團在渠道佈局上的精準和高效。在零售運營方面,上半年集團深化單店經營模式的創新與實踐,有效推動零售運營標準的全面落地。通過終端門店銷售計劃系統的全面推進與核心門店的系統落地,實現門店管理效率的顯著提升。在新零售業務方面,集團通過數字化轉型,強化社群運營和內容創造,實現私域流量的高效轉化,銷售額與轉換效率均實現有效提升。此外,集團積極探索多元化商業模式,包括通過抖音等社交平台引流及與核心渠道的線上業務合作,不斷為終端銷售注入新動力,提升門店的離店銷售佔比,進一步增強門店經營效率。在電商運營方面,李寧電商繼續專注於專業功能類產品的突破,尤其在跑步鞋領域實現快速增長,專業實戰籃球鞋產品亦鞏固了市場領先地位;此外,在線上專供單品領域,集團成功打造多款在業界獲得體量與口碑的單品。期內,集團通過線上線下渠道的有效整合與創新實踐,實現電商業務與零售運營的協同增長,推動銷售業績的顯著提升和市場份額的進一步加強。童裝業務方面,李寧YOUNG對青少年產品矩陣進行深入梳理,明確服裝和配飾的核心競爭力,完善鞋類產品矩陣。營銷方面,李寧YOUNG整合市場營銷資源,積極探索全渠道營銷及社群運營,並通過與籃球明星韋德合作,提升品牌影響力;積極開展各類會員社群活動、打造全新的運動明星進店開業活動,助力門店引流。截至2024年6月30日,於中國,李寧YOUNG銷售點數量共計1,438個,較上一季末淨增加33個,本年迄今淨增加10個。集團將繼續深入發展李寧YOUNG業務,聚焦產品,提升產品核心科技與設計,深耕市場需求及品類規劃,同時強化品牌推廣,推動李寧YOUNG成為中國兒童首選的專業運動童裝品牌。前景展望集團將繼續踐行「單品牌、多品類、多渠道」的核心戰略,不斷強化產品力,並通過整合營運資源,務求以高效的企業組織能力,推動集團實現穩健且持續的增長:– 基本面業務穩健發展:集團將持續深化李寧品牌的市場影響力,重點發展跑步、籃球、健身、羽毛球和運動生活五大核心品類。通過研發創新投入,實現產品矩陣的持續升級,以滿足消費者對高質量、個性化運動裝備日益增長的需求,鞏固並擴大集團在核心領域的市場領導地位;– 產品結構優化升級:集團將進一步升級單品牌戰略下多元化的產品矩陣,順應市場趨勢和消費者偏好的演變,充分發揮「中國李寧」及「LI-NING 1990」在運動生活領域的補充作用,拓展多元的穿搭場景,增強品牌在多元場景下的競爭力;– 放眼未來擇機破局:集團將積極探索破局,率先切入體育消費新賽道,挖掘女子、戶外和青少年市場的巨大潜力,制定針對性的營銷策略,推出符合目標群體需求的產品,力求在這些新領域取得突破;– 優化市場拓展策略:為了實現全面的市場覆蓋,集團將優化現有高層級市場的資源分配,提高市場效率。同時,積極開拓新興市場,並制定針對海外市場的策略,力求在保持穩健步伐的同時,海外市場可實現破局。集團執行主席兼聯席行政總裁李寧先生總結:「國家一系列深化市場改革政策扎實推進將為集團提供公平且更有活力的市場環境、開闢更為廣闊成長空間。集團將恪守既定的發展戰略,依託品牌的專業運動基因,持續為大眾推出優質的體育用品。與此同時,集團將繼續深耕中國市場,並乘奧運東風,秉持『一切皆有可能』的精神,推動中國體育產業走向國際舞台。」- 完 -關於李寧有限公司李寧有限公司是中國領先的體育品牌企業之一,以經營李寧品牌專業及休閑運動鞋、服裝、器材和配件產品為主。集團總部位於北京,擁有品牌營銷、研發、設計、製造、經銷及零售能力,目前已於中國建立龐大的零售分銷網絡以及供應鏈管理體系。集團致力於成為源自中國並被世界認可的、具有時尚性的國際一流專業運動品牌企業。除核心品牌李寧牌外,集團亦生產、開發、推廣、分銷、銷售多個自有、特許或與集團第三方設立的合資╱聯營企業經營的其他品牌體育產品,包括紅雙喜乒乓球產品、AIGLE(艾高)戶外運動用品、Danskin舞蹈和瑜伽時尚健身產品及Kason(凱勝)羽毛球產品。 Copyright 2024 亞太商訊 via SeaPRwire.com.

Japan Buys Two SeaGuardians From GA-ASI

SAN DIEGO, CA, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - The Japan Coast Guard (JCG) has signed a contract for the purchase of two SeaGuardian® Remotely Piloted Aircraft (RPA) from General Atomics Aeronautical Systems, Inc. (GA-ASI), scheduled for delivery in 2025. This follows JCG's ongoing Company-Owned, Contractor-Operated agreement with GA-ASI for operating SeaGuardian, which began in April 2022."Since JCG started operating SeaGuardians, they have been used for various JCG missions, including supporting search and rescue and disaster response, specifically during the 7.6 magnitude earthquake early this year near the Noto Peninsula of Ishikawa Prefecture and maritime surveillance during the 2023 G-7 Summit in Hiroshima, and the system has performed efficiently and effectively," said GA-ASI CEO Linden Blue.SeaGuardian is a medium-altitude, long-endurance RPA system that can fly for 24 hours or more, depending on the configuration.GA-ASI has strengthened its Maritime Wide Area Surveillance (MWAS) for Japan with Optix+, which gathers information from the SeaGuardian sensors, as well as other data sources, displaying the full picture of surveillance information for its operator. This functionality makes it easy to task and direct its Intelligence, Surveillance and Reconnaissance (ISR) information in real time. GA-ASI's Optix+ software suite rapidly correlates and exploits collected data into an easily shared common operational picture. Having multi-source correlated data enables automatic detection of anomalous behaviors over waters.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.For more information, visit www.ga-asi.com.Avenger, Lynx, Predator, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.

“Launch from Greater Bay Area: Nanhai I Shipwreck and the Maritime Silk Road” exhibition opens

HONG KONG, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - The opening ceremony of the exhibition entitled "Launch from Greater Bay Area: Nanhai I Shipwreck and the Maritime Silk Road", co-organised by the Development Bureau (DEVB), the National Cultural Heritage Administration and the Secretariat for Social Affairs and Culture of the Government of the Macao Special Administrative Region, was held on August 15. Featuring artefacts discovered from Nanhai I, an ocean-going merchant ship, and relevant artefacts from Guangdong, Hong Kong and Macao, the exhibition showcases the role of the Guangdong-Hong Kong-Macao Greater Bay Area on the Maritime Silk Road.  The opening ceremony was officiated by the Secretary for Development, Ms Bernadette Linn; Deputy Director of Art Exhibitions China Ms Zhou Yu; the President of the Guangdong Provincial Institute of Cultural Relics and Archaeology, Ms Cao Jin; and the Vice President of the Cultural Affairs Bureau of the Government of the Macao Special Administrative Region, Mr Cheang Kai-meng.Nanhai I was a merchant ship of the Southern Song dynasty. Its shipwreck was salvaged in 2007 and is the most complete ancient ocean-going merchant ship discovered through archaeological excavation to date. A large collection of artefacts was discovered from Nanhai I, mainly porcelain, bronzeware, ironware, gold, silverware, lacquerware and woodenware. The quantities, shapes, craftsmanship and forms of the artefacts are rare among the archaeological finds of the Southern Song dynasty. Archaeologists believe that Nanhai I might have sunk along the maritime route from Guangdong to the South China Sea in the 10th year of the Chunxi reign (1183) of the Southern Song dynasty or shortly afterwards.  Among the 255 items of exhibits are artefacts discovered from Nanhai I, including a brown glazed jar with four lugs and stamped with the Chinese characters “Chun Xi Shi Nian” (i.e. the 10th year of the Chunxi reign) from the Nanhai kiln; a qingbai glazed foliated bowl with stamped plum blossom pattern from the Jingdezhen kiln; a green glazed ogee-shaped foliated dish with incised lotus pattern from the Longquan kiln; a necklace with gold chain and rhinoceros horn-shaped cone ornaments; and a gem-set hollow gold bracelet. Also on display are relevant exhibits unearthed from Guangdong, Hong Kong and Macao, including the bottom fragment of a qingbai glazed bowl with inked Chinese characters “Gong Shi” (i.e. envoy) from the Hutian kiln of the Song dynasty from the site of the Nanyue Kingdom Palace in Guangzhou; a yellowish-green glazed jar with six lugs and dragon pattern of the Song dynasty from the site of the former Sacred Hill in Hong Kong; and a blue-and-white kendi with elephant head shaped spout from the Jingdezhen kiln of the Ming dynasty from the site of St. Paul's College in Macao.The exhibition will run at the Hong Kong Heritage Discovery Centre, Kowloon Park, Haiphong Road, Tsim Sha Tsui, from August 16 to February 12 next year. Admission is free. A short video about the preparation of the exhibition is available on the website of the Antiquities and Monuments Office of the DEVB (www.amo.gov.hk/en/news/index_id_153.html?year=2024).  The exhibition entitled “Launch from Greater Bay Area: Nanhai I Shipwreckand the Maritime Silk Road” opened on August 15. Photo shows the Secretaryfor Development, Ms Bernadette Linn (second right); the Deputy Directorof Art Exhibitions China, Ms Zhou Yu (second left); the President ofGuangdong Provincial Institute of Cultural Relics and Archaeology,Ms Cao Jin (first right); and the Vice President of the CulturalAffairs Bureau of the Government of the Macao Special AdministrativeRegion, Mr Cheang Kai-meng (first left), officiating at the opening ceremony.The exhibition entitled “Launch from Greater Bay Area: Nanhai I Shipwreckand the Maritime Silk Road” opened on August 15. Photo shows the Secretaryfor Development, Ms Bernadette Linn (first left), the Deputy Directorof Art Exhibitions China, Ms Zhou Yu (third right), and the VicePresident of the Cultural Affairs Bureau of the Governmentof the Macao Special Administrative Region, Mr Cheang Kai-meng(second right) touring the exhibition.The exhibition entitled “Launch from Greater Bay Area: Nanhai I Shipwreckand the Maritime Silk Road” opened on August 15. Photo shows theSecretary for Development, Ms Bernadette Linn (first left), the DeputyDirector of Art Exhibitions China, Ms Zhou Yu (second left), and theVice President of the Cultural Affairs Bureau of the Government of theMacao Special Administrative Region, Mr Cheang Kai-meng (third left)touring the exhibition.Brown glazed jar with four lugs and stamped Chinesecharacters “Chun Xi Shi Nian” (i.e. the tenth yearof the Chunxi reign) from Nanhai kiln. The inscriptionon the jar is crucial for determining when the"Nanhai I" sank.Gem-set hollow gold bracelet with sophisticated techniques of SouthernSong dynasty (1127-1279) unearthed at “Nanhai I”, similarartefacts were also found at Riyadh, Saudi Arabi.Green glazed ogee-shaped foliated dish with incised lotus pattern ofSouthern Song dynasty (1127-1279) from Longquan kiln unearthed at “Nanhai I”.  Copyright 2024 ACN Newswire via SeaPRwire.com.

WL Delicious Announced 2024 Interim Results

HONG KONG, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - Weilong Delicious Global Holdings Ltd (“WL Delicious” or the “Company”) and together with its subsidiaries (the “Group”) (Hong Kong stock code: 9985.HK) announced its unaudited interim results for the six months ended 30 June 2024 (the “Reporting Period”).In the first half of 2024, against the backdrop of increasing global uncertainties, the Chinese economy maintained a robust growth momentum. Benefiting from the growing consumption willingness of young consumer groups led by Generation Z, the casual snack food industry has exhibited strong growth prospects. During the Reporting Period, WL Delicious seized the structural opportunities in the snack food sector brought by diversified mainstream consumption concepts, adhering to the strategy of "multiple categories and large single product". The Company continuously upgraded its research and development capabilities, actively engaged in integrated online and offline marketing activities to enhance brand influence, and vigorously implemented its omni-channel strategy to provide consumers with a more satisfying, convenient, and superior consumption experience.During the Reporting Period, WL Delicious's operational strategy yielded significant results, with performance continuously improving and achieving double-digit growth in both revenue and net profit. In the first half of 2024, the Group’s total revenue reached approximately RMB 2,939 million, representing a year-on-year growth of 26.3%. This growth was primarily attributed to the effective implementation of the Group’s business development strategies during the Reporting Period, particularly the active promotion of omni-channel construction and brand investment and brand building, resulting in the steady increase in both online and offline revenues. Benefiting from an increase in utilization rate and a decrease in the prices of certain raw materials during the Reporting Period, the Group recorded a gross profit of approximately RMB 1,462 million, marking a 32.2% year-on-year increase. The gross profit margin increased by 2.3 percentage points from the same period last year to 49.8%. The Group's net profit surged by 38.9% year-on-year to around RMB 621 million. Driven by the improvements in revenue and gross margin, the net profit margin increased by 1.9 percentage points from the same period last year to 21.1%.Based on the overall performance during the Reporting Period, the Board of Directors decided to declare an Interim Dividend of RMB 0.16 per share (inclusive of tax for 2024, amounting to a total Interim Dividend of approximately RMB376.2 million), representing approximately 60% of the net profit of the Group for the six months ended June 30, 2024. The expected dividend payment date is on or about October 18, 2024.In terms of products, the Group adhered to its consumer-centric approach andmaintained the strategy of "multiple categories and large single product". It actively enhanced its research and development capabilities, continuously explored the changing consumption preferences of young consumer groups, and successively launched products such as spicy barbecue-flavored konjac vegetarian tendon "XIAO MO NV", hot and sour hotpot-flavored vegetarian tripe "XIAO MO NV", and lime-flavored crisp Latiao “CUI HUO HUO”, expanding its product portfolio to meet the diverse and personalized consumer demands.In terms of brand development, the Group continued to strengthen its branding efforts. It actively engaged in integrated online and offline branding and marketing activities to enhance interaction with consumers and boost brand influence. Activities including brand promotion of the core large product "Konjac Shuang," IP animated videos for the " XIAO MO NV", "Durian Latiao" pop-up stores, and collaborative marketing events like the " Eggy Party" were organised. The Group has been actively creating a distinct path towards brand rejuvenation, aiming to continuously increase brand vitality and appeal. This makes the brand more aligned with the lifestyle and consumption habits of young consumer groups.Regarding distribution channels, the Group actively implemented its omni-channel strategy. While consolidating its presence in traditional snack distribution channels, it was also seizing growth opportunities brought by emerging channels such as O2O, content e-commerce platforms, snack specialty retailers, and warehouse clubs. During the Reporting Period, the Group deepened its online and offline omni-channel development, establishing closer connections with consumers and providing a more convenient consumption experience.Mr. Liu Weiping, Chairman of WL Delicious, stated: "As a pioneer and leader in the Chinese spicy snack food industry, the Group remains committed to embracing the diverse changes in consumer preferences with a more proactive and open mindset. We actively strengthen our product category and product innovation, promote youthful and diverse development of our brand, seize the opportunities brought by the emerging channels while reinforcing traditional channels, firmly advocate for product innovation and omni-channel development, and remain focused on enhancing the quality and efficiency of our supply chain. We are dedicated to continuously establishing ourselves as a leading provider of value-driven spicy snack foods for consumers. The Group will continue to stay true to our original aspirations, remember our mission, and strive to deliver the maximum value and return to consumers, customers, shareholders, investors, employees, and society."RMBFor the 6 months ended 30 JuneChange20242023Revenue2,939 million2,327 million+26.3%Gross Profit1,462 million1,106 million+32.2%Gross Profit Margin49.8%47.5%+2.3p.p.Net Profit621 million447 million+38.9%Net Profit Margin21.1%19.2%+1.9p.p.Basic Earnings Per Share0.270.19+42.1%Interim Dividend0.16 / ordinary share0.12 / ordinary share+33.3%- Ends -About Weilong Delicious Global Holdings LtdWEILONG Delicious Global Holdings Limited ("WL Delicious") is an all-in-one spicy snack products enterprise, leading in the research and development, production, and sales of spicy snack foods in China. Based on traditional formulas, WL Delicious started the Chinese seasoned flour products (also commonly known as Latiao industry, created our first Latiao snack in 2001, leading the standards construction of Latiao industry. With our outstanding product development capabilities, the Group has successfully diversified into vegetable products, bean-based products and others, including Konjac Shuang, Fengchi Kelp, Soft-boiled egg and others. The Group has further launched new products like spicy Latiao, konjac vegetarian tripe “XIAO MO NV” and spicy crisp Latiao “CUI HUO HUO”, which are quite popular among consumers. WL Delicious is a popular snack food brand among young consumers in China. It has an omni-channel sales and distribution network that effectively reaches young consumers. In 2024, we have won the FBIF WOW Food Award "Best Snack Award" ( FBIF WOW and "Hurun Top 100 National Brands" award. For more information, please visit https://www.weilongshipin.com/.    Copyright 2024 ACN Newswire via SeaPRwire.com.